



PHYTO CHEM (INDIA) LIMITED

CIN : L24110TG1989PLC009500

Corporate Office : 8-3-229/23, First Floor, Thaherville,
Yousufguda Checkpost, Hyderabad-500 045, Telangana.
Tel : 040 - 23557712, 23557713, Fax : 91-40-23557714.
Email : info@phytochemindia.com

PCIL/BSE/2020-21/AR/0142/2021-22

Date: 03-09-2021

To
M/s Bombay Stock Exchange Limited,
Floor 25, PJ Towers,
Dalal Street,
Mumbai – 400001,
Tel: 022-22721234/33

Kind Attn: Dept. of Corporate Services.

Dear Sir (s),

Sub: Submission of Annual Report for the Financial Year 2020-2021 under
Regulation 34 of Securities and Exchange Board of India (LODR),
Regulations, 2015- Regarding.
Ref: BSE Script Code – 524808.


With reference to the subject cited above, we hereby furnish the Annual Report for the Financial Year 2020-2021 as per the Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and record.

Thanking you

Yours faithfully
For Phyto Chem (India) Limited

(Y.Nayudamma)
Managing Director
DIN: 00377721



Encl: as above.



***Thirty Second Annual Report
2020-21***



Phyto Chem (India) Limited



Phyto Chem (India) Limited

Factory Premises



Phyto Chem - Annual Report - 2020-21

Board of Directors

Dr. P. Sreemannarayana	-	Chairman
Mr. Y. Nayudamma	-	Managing Director
Mr. Y. Janaki Ramaiah	-	Executive Director
Dr. Y. Venkateswarlu	-	Director
a. Mr. K. Srinivasa Rao	-	Alternate Director
Mr. P. Anjaneyulu	-	Director
Mr. T. A. Choudary	-	Independent Director - upto 12-11-2020
Mr. N. Sudhakar	-	Independent Director - upto 12-11-2020
Mrs. S. Kavitha Rani	-	Independent Director - upto 12-11-2020
Dr. G. S. R. Anjaneyulu	-	Independent Director
Mr. M. Sree Ram Murthy	-	Independent Director
Mr. K. Ravindra Babu	-	Independent Director - w.e.f. 28-12-2020
Mr. S. Y. Sampath Kumar	-	Independent Director - w.e.f. 28-12-2020
Mrs. G. Vijitha	-	Independent Director - w.e.f. 28-12-2020
Mr. Pavansingh Thakur	-	Company Secretary & Compliance Officer
Mr. B. Sambasiva Rao	-	Chief Financial Officer

Auditors

M/s. S. T. Mohite & Co.,
Chartered Accountants,
Hyderabad.

Secretarial Auditors

M/s. Puttaparthi Jagannatham & Co.,
Company Secretaries
No.315, Bhanu Enclave,
Near ESI, Sundar Nagar, Hyderabad - 500 038.

Bankers

M/s. The Federal Bank Limited,
Hyderabad Branch, Bank Street, Koti, Hyderabad - 500 001.

Common Share Transfer Agents

(Physical & Electronic)

M/s. Bigshare Services Pvt. Limited,
No.306, 3rd Floor, Right Wing,
Amrutha Ville, Opp: Yashoda Hospital,
Raj Bhavan Road, Somajiguda, Hyderabad - 500 082.
Phone No : 040-23374967.

Corporate Office

No.8-3-229/23, First Floor,
Thaherville, Yousufguda Checkpost, Hyderabad - 500 045.
Phone No : 040-23557712, 23557713.

Registered Office & Factory

Survey No.628, Temple Street,
Bonthapally - 502 313, Gummadidala (M), Sangareddy Dist., T.S.



Phyto Chem (India) Limited

Notice of AGM

Notice is hereby given that the Thirty Second Annual General Meeting of the Members of M/s Phyto Chem (India) Limited (CIN: L24110TG1989PLC009500) will be held on Monday, the 27th day of September 2021 at 11:45 A.M. at the Registered Office of the Company at Survey No.628, Temple Street, Bonthapally - 502 313, Gummadida Mandal, Sangareddy District, Telangana State to transact the following business:

Ordinary Business:

1. To receive, consider and adopt the Audited Balance Sheet as at 31st March 2021, Profit and Loss Account and Cash Flow Statement for the year ended on that date along with the Reports of the Board of Directors and Auditors thereon.
2. To appoint a Director in place of Dr. Sreemannarayana Prathipati (DIN: 00377472), who retires by rotation and being eligible, offers himself for reappointment.

Special Business:

3. Continuation of Directorship of Dr. Sreemannarayana Prathipati (DIN: 00377472) as a Non-Executive Non-Independent Director in terms of Regulation 17(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To consider and if thought fit, to pass with or without modification(s) the following resolution as Special Resolution:

"RESOLVED THAT pursuant to Regulation 17(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the applicable provisions of the Companies Act, 2013 and relevant rules framed thereunder (including any statutory modification or re-enactment thereto), approval of members be and is hereby accorded to the continuation of Directorship of Dr. Sreemannarayana Prathipati (DIN: 00377472) as a Non-Executive Non Independent Director of the Company, liable to retire by rotation."

For and on behalf of the Board

Place : Hyderabad
Date : 14th August 2021

Y.Nayudamma
Managing Director
DIN: 00377721

Phyto Chem - Annual Report - 2020-21

Notes

1. A member entitled to attend and vote at the Annual General Meeting is entitled to appoint a proxy to attend and vote on poll instead of himself/herself and a proxy need not be a member of the Company. The instrument of Proxy in order to be effective should be deposited at its Registered Office of the Company not later than forty eight hours before the commencement of the meeting.

A person can act as a proxy on behalf of members not exceeding fifty and holding in the aggregate not more than ten percent of the total share capital of the Company carrying voting rights. A member holding more than ten percent of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholders.
2. The Register of Members and Share Transfer Books of the Company will remain closed from 21-09-2021 to 27-09-2021 (both days inclusive) for the purpose of the meeting.
3. Electronic copy of the Annual Report and the Notice of the Annual General Meeting of the Company 'inter-alia' indicating the process and manner of e-voting along with Attendance Slip and Proxy Form are being sent to all the members whose email IDs are registered with the Company / Depository Participants(s) for communication purposes, unless any member has requested for a hard copy of the same. For members who have not registered their email address, physical copies of the above documents are being sent in the permitted mode.
4. Members are requested to notify any change in their addresses to the Company or Registrar and Transfer Agent. Members holding shares in electronic form are requested to advise change of address, email IDs and Bank details to their Depository Participants.

The Members are aware that the Company's shares are tradable compulsorily in electronic form and your Company has established connectivity with Central Depository Services (India) Limited (CDSL) and National Securities Depository Limited (NSDL). In view of the numerous advantages offered by the depository system, the Members are requested to avail the facility of Dematerialisation of the Company's shares on NSDL or CDSL. The ISIN allotted to the Company's Equity shares is INE 037C01010.
5. Members are requested to affix their signatures at the space provided on the Attendance Slip annexed to Proxy Form and handover the Slip at the entrance of the meeting hall. The Corporate members are requested to send a duly certified copy of the Board resolution / power of attorney authorising their representatives to attend and vote at the Annual General Meeting.
6. Members may also note that the Notice of the Annual General Meeting and the Annual Report will also be available on the Company's website for their download. The physical copies of the aforesaid documents will also be available at the Company's Registered Office at Survey No.628, Temple Street, Bonthapally – 502 313, Gummadidala Mandal, Sangareddy District, Telangana State for inspection during normal business hours on all working days. Even after registering for e-communication, members are entitled to receive such communication in physical form upon making a request for the same by post at free of cost.
7. The details of the unpaid/unclaimed dividend declared for the F.Y 2013-14 as on 24th September 2015 is available on the Company's website www.phytochemindia.com and on the website of Ministry of Corporate Affairs at www.mca.gov.in.
8. **Voting through Electronic means:**
 - a. The Company is pleased to provide members the facility to exercise their right to vote on the resolutions as set out in the Notice calling for the Annual General Meeting (AGM) by 'electronic means' and all the business may be transacted through e-Voting services provided by Central Depository Services (India) Limited (CDSL), in compliance with the provisions of Section 108 of the Companies Act, 2013 and Rule 20 of the



Phyto Chem (India) Limited

Companies (Management and Administration) Rules, 2014.

- b. Voting rights are reckoned on the basis of the shares registered in the names of the members / beneficial owners as on the record date fixed for this purpose viz., 20-09-2021.
- c. CS Puttaparthi Jagannatham, Corporate Advocate has been appointed as scrutinizer for conducting the e-Voting process in a fair and transparent manner.
- d. Members are requested to read the instructions given below:
- e. The E-Voting facility is available at the link:

EVSN (e – Voting Sequence Number)	Commencement of e-Voting	End of e-Voting
210825010	24-09-2021	26-09-2021

In case of members receiving e-mail:

- i. Log on to the e-voting website: www.evotingindia.com
- ii. Click on “Shareholders” tab to cast your votes.
- iii. Now, select the “EVSN” along with “PHYTO CHEM (INDIA) LIMITED” from the drop down menu and click on “SUBMIT”
- iv. Now Enter your User ID
 - a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Members holding shares in Physical Form should enter Folio Number registered with the Company.
- v. Next enter the Image Verification as displayed and Click on Login.
- vi. If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier voting of any Company, then your existing password is to be used.
- vii. If you are a first time user, follow the steps given below:

	For Members holding shares in Demat Form and Physical Form
PAN*	<p>Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders)-</p> <p>* Members who have not updated their PAN with the Company/Depository Participant are requested to use the first two letters of their name and the last 8 digits of the demat account/folio number in the PAN field.</p> <p>* In case the folio number is less than 8 digits enter the applicable number of 0's before the number after the first two characters of the name in CAPITAL letters. Eg. If your name is Ramesh Kumar with folio number 100 then enter RA00000100 in the PAN field.</p>
DOB#	Enter the Date of Birth as recorded in your demat account or in the Company records for the said demat account or folio in dd/mm/yyyy format.
Dividend Bank Details#	<p>Enter the Dividend Bank Details as recorded in your demat account or in the Company records for the said demat account or folio.</p> <p>* Please enter the DOB or Dividend Bank Details in order to login. If the details are not recorded with the depository or Company, please enter the number of shares held by you as on the cut off date in the Dividend Bank details field.</p>

- viii. After entering these details appropriately, click on “SUBMIT” tab.
- ix. Members holding shares in physical form will then reach directly the Company selection screen. However, members holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting on the resolutions of any other Company on which they are eligible to vote, provided that Company

Phyto Chem - Annual Report - 2020-21

opts for e-voting through CDSL platform . It is strongly recommended not to share your password with any other person and take utmost care to keep your password is confidential.

- x. For Members holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
 - xi. Click on the relevant EVSN on which you choose to vote.
 - xii. On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
 - xiii. Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.
 - xiv. After selecting the resolution if you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.
 - xv. Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.
 - xvi. You can also take out print of the voting done by you by clicking on "Click here to print" option on the Voting page.
 - xvii. If Demat account holder has forgotten the changed password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- * Institutional shareholders (i.e. other than Individuals, HUF, NRI etc.) are required to log on to <https://www.evotingindia.co.in> and register themselves as Corporates.
 - * They should email a scanned copy of the Registration Form bearing the stamp and sign of the entity helpdesk.evoting@cdslindia.com.
 - * After receiving the login details, they have to create a compliance user using the admin login and password. The compliance user would be able to link the account(s) which they wish to vote

- * The list of accounts should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.

- * They should upload a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, in PDF format in the system for the scrutinizer to verify the same.

In case of members receiving the physical copy:

- A. Please follow all steps from S.No. i to S.No. xvii of notes.8.e. above to cast vote.
- B. The e-voting period begins from 9:00 am on Friday, the 24th September 2021 and closes by 5:00 pm on Sunday, the 26th September 2021. During this period, shareholders' of the Company, holding shares either in physical form or in dematerialised form, as on the cut-off date (holding date) i.e Monday, 20th September 2021, may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- C. In case you have any queries or issues regarding e-voting, you may refer the Frequently Asked Questions ("FAQs") and e-voting manual available at www.evotingindia.co.in under help section or write an email to helpdesk.evoting@cdslindia.com.
- D. The Scrutinizer shall within a period not exceeding three working days from the conclusion of the e-Voting period unblock the votes in the presence of at least two witnesses not in the employment of the Company and make a Scrutinizer's Report of the votes cast "in favour" or "against", if any, forthwith to the Chairman of the Company.
- E. The results declared along with the Scrutinizer's Report will be placed on the Company's website www.phytochemindia.com and on the website of CDSL within two days of passing of the resolutions at the AGM and communicated to the Stock Exchange.
- F. All documents referred to in the accompanying Notice and the Explanatory Statement will be open for inspection at the Registered Office of the Company during normal business hours on all working days upto and including the date of the AGM.



Phyto Chem (India) Limited

Additional information about the Directors being appointed / reappointed as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Item No.2. Re-appointment of Dr. Sreemannarayana Prathipati as Director of the Company.

Dr. Sreemannarayana Prathipati (DIN: 00377472) aged about 74 years, is a Post Graduate in Medicine, Non-Resident Indian and he had worked for more than 30 years in U.S.A. He has been the Chairman of the Company since 1995. He is presently residing in India.

Item No.3. Continuation of Directorship of Dr. Sreemannarayana Prathipati as a Non-Executive Non- Independent Director in terms of Regulation 17(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dr. Sreemannarayana Prathipati (DIN: 00377472), is a Non-Resident Indian aged about 74 years is a Post Graduate in Medicine (M.D.), had worked for more than 30 years in U.S.A. and he holds 1,25,100 Equity Shares in the Company. Since, Dr. Sreemannarayana Prathipati will be exceeding 75 years in the coming Financial Year, It is to be considered necessary to continue his directorship on the Board of Directors of the Company.

Explanatory Statement:

This explanatory statement is provided as per Section 102 of the Act.

Special Business:

Item No.3

Continuation of Directorship of Dr. Sreemannarayana Prathipati (DIN: 00377472) as a Non-Executive Non-Independent Director in terms of regulation 17(1A) of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

As per Regulation 17(1A) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") with effect from April 1, 2019, no listed Company shall appoint or continue the directorship of a Non-Executive Director who has attained the age of 75 (Seventy Five) years, unless a Special Resolution is passed to that effect and justification thereof is indicated in the explanatory statement annexed to the Notice for such appointment.

Dr. Sreemannarayana Prathipati (DIN: 00377472) is a Non-Executive Director of the Company liable to retire by rotation.

Dr. Sreemannarayana Prathipati (DIN: 00377472) has been a Director of the Company from 05th December 1994. Since he will be exceeding 75 years in the coming Financial Year and his services are felt beneficial to the Company and hence it is considered necessary to approve his Directorship on the Board of Directors of the Company.

The Nomination and Remuneration Committee and the Board of Directors of the Company have recommended the continuation of directorship of Dr. Sreemannarayana Prathipati (DIN: 00377472) as a "Non- Executive Director" of the Company, considering his rich experience, knowledge, expertise, continued valuable guidance and immense contribution in the growth of the Company.

The Members may approve by way of passing a Special Resolution for the continuation of directorship of Dr. Sreemannarayana Prathipati (DIN: 00377472) as a 'Non- Executive Director' of the Company, liable to retire by rotation.

The Board of Directors recommends the Special Resolution set forth in Item No. 3 for approval of the Members.

Disclosure under Regulation 36(3) of the Listing Regulations and Secretarial Standard- 2 issued by the Institute of Company Secretaries of India are set out in the Annexure to the Explanatory Statement.

Except the Director who is being appointed, none of the other Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the resolution set out at Item No.3.

For and on behalf of the Board

**Y.Nayudamma
Managing Director
DIN: 00377721**

**Place : Hyderabad
Date : 14th August 2021**

Phyto Chem - Annual Report - 2020-21

Directors' Report

Dear Shareholders,

Your Directors have pleasure to present the 32nd Annual Report of the Company together with the Audited Accounts for the financial year ended 31st March 2021 along with Auditors' Report thereon.

1. Financial Results :

The Financial Results for the year ended 31st March 2021 are summarised as under:

(Rs. in lacs)

Particulars	Current Year 2020-21	Previous Year 2019-20
Sales	5243.01	5210.45
Less: GST	794.21	788.17
Net Sales	4448.80	4422.28
Other operating Income	80.47	138.26
Total Income from operations (Net)	4529.27	4560.54
Profit before finance cost, depreciation & amortisation	300.91	330.16
Finance Cost	211.68	246.94
Profit Before Depreciation & Amortisation	89.23	83.22
Depreciation & Amortisation	42.58	40.96
Profit/(Loss) Before Tax	46.65	42.26
Provision for Taxation		
Current Tax	19.00	13.50
Deferred Tax	(21.65)	(15.81)
Net Profit/(Loss) for the Period	49.30	44.57
EPS (Basic) Rs.	1.15	1.04

2. Indian Accounting Standards:

The Company has followed Indian Accounting Standards and accounting principles generally accepted in India in preparation of financial statements for the financial year 2020-21.

3. Performance:

Your Company has registered a turnover of Rs. 4529.27 lakhs during the year 2020-21 as against the turnover of Rs. 4560.54 lakhs during the previous year. The Company could make profit of Rs. 46.65 lakhs during the financial year 2020-21 before taxes as against Rs.42.26 lakhs during the previous year. After providing for taxes, the Company could make net profit of Rs. 49.30 lakhs during the financial year 2020-21 as against net profit of Rs. 44.57 lakhs during the financial year 2019-20. The profitability of the Company has slightly increased when compared to previous year and could not achieve estimated turnovers due to heavy competition, shortfall of rains in many places in the Country.

During the year 2020-21, the turnover decreased by 0.69 % as compared to the turnover of 2019-20. The ratio of manufacturing expenses to the Sales during the year 2020-21 is 80.03% as against 80.54% during 2019-20. The ratio of Administrative, Selling and Other expenses to the total expenditure is 10.59% during the year 2020-21 as against 9.66% during 2019-20.



Phyto Chem (India) Limited

4. Review of Operations:

a. Brief about Activities and Operations of the Company:

Your Company is mainly into the business of manufacturing & marketing of Pesticides for agriculture sector and presently carrying on the business in two segments i.e. Pesticides Formulations and Real Estate Activities.

The main focus is on the Pesticides Business and the following manufacturing facilities for various pesticides formulations are available at the Factory:

- i. Liquid & SC Formulations
- ii. Weedcide Formulations
- iii. Wettable & Powder Formulations
- iv. Granule Formulations

Presently, the Company has Production Capacity of 90,00,000 Ltrs/Kgs per annum to manufacture various pesticides formulations and has established its marketing network in the states of Telangana, Andhra Pradesh, Maharashtra and Karnataka. The products are marketed with its own brands through dealers & distributors network. The Company is continuing Real Estate activity in a small way in Bengaluru for the last few years. The Company has also started business in the Food Sector very recently in a small way.

b. Performance of the Company:

The Company has achieved a turnover of Rs. 4529.27 lakhs during the year 2020-21 as against turnover of Rs. 4560.54 lakhs during the previous year. Though Company has taken steps such as establishing new sales divisions and continuous introduction of new products to match with current needs of the market, the Company could not achieve the projected sales due to shortfall of rains in many states of the country and competition of the products. The Company has registered a small turnover in the Food Division during the year.

c. Prospects for the Financial Year 2021-22:

The Company estimates a turnover of Rs. 90.05 crores during the current year 2021-22. Since the Primary business of the Company is Agri related, monsoon conditions play major role in achieving the turnovers. The Company is hopeful of improving turnovers with the established marketing network. As on date, the Company's deployment of funds in Real estate is Rs.96.79 lakhs and hopes to encash the opportunities available in the real estate field at Bengaluru with good margins during the financial year 2021-22. The Company is hopeful of good turnovers with margins in the Food Division during 2021-22.

5. Dividend:

In order to conserve its financial resources to meet its estimated plan, your Board could not recommend any dividend for the year under review.

6. Change in the nature of Business:

During the year under review, there has been no change in the nature of business of the Company.

7. Details of Subsidiary / Joint Ventures / Associate Companies:

The Company does not have any Subsidiaries or Joint Ventures or Associate Companies.

8. Finance:

Cash and cash equivalents as at 31st March 2021 was Rs.12.60 lakhs. The Company continues to focus on judicious management of its working capital, receivables, inventories and other working capital parameters and they were kept under strict check through continuous monitoring at all levels.

9. Material changes and Commitments, affecting the Financial Position of the Company:

There were no material changes and commitments affecting the financial position of the Company from the year ended 31st March 2020 to till the date of this report.

Phyto Chem - Annual Report - 2020-21

10. Details of Significant and Material Orders passed by the Regulators / Courts / Tribunals impacting the going concern status and the Company's operations infuture:

There are no significant and material orders passed by the Regulators or Courts or Tribunals which would impact the going concern status, growth and operations of the Company in future.

11. Share Capital:

The authorised share capital of the Company is Rs.13,50,00,000 divided into 1,35,00,000 equity shares of Rs.10/- each. The paid up share capital is Rs. 4,30,02,000 divided into 43,00,200 equity shares of Rs.10/- each. There were no other changes that have been made in the share capital of the Company during the year under review. The Details of Share Capital are mentioned at Notes-12 of the Financial Statements.

12. Reserves:

The Reserves in Profit & Loss account as per last Balance Sheet is Rs. 5,54,75,904 and the Company transferred the profits of Rs.33,67,299 after adjusting retained reserve for gratuity fund for the financial year 2020-21 to Reserves & Surplus account. The balance in reserves and surplus available at the end of the year 2020-21 is Rs. 5,88,43,203. Further details of Reserves & Surplus are mentioned at Notes-13 of the Financial Statements.

13. Details in respect of adequacy of internal financial controls with reference to the financial statements:

Based on the framework of internal financial controls and compliance systems established and maintained by the Company, work performed by the Internal, Statutory and Secretarial Auditors including audit of internal financial controls over financial reporting by the Statutory Auditors and the reviews performed by management and the relevant Board Committees, including the Audit Committee, the Board is of the opinion that the Company's internal financial controls are adequate and effective during the period ended on 31st March 2021.

14. Corporate Social Responsibility (CSR):

The compliance of the Provisions of CSR criteria mentioned in the provisions of Companies Act, 2013 are not applicable for the Company as on date.

15. Deposits:

The Company has not accepted any fixed deposits from the public during the year.

16. Particulars of Loans, Guarantees or Investments under Section 186 of the Companies Act, 2013:

The Company has not granted any Loans, given Guarantees or made any Investments in any other Companies during the year under Section 186 of the Companies Act, 2013.

17. Extract of Annual Return:

The extract of Annual Return of the Company is given in Annexure - I in the prescribed Form MGT-9, which forms part of this Report as required under Section 92(3) of the Companies Act, 2013.

18. Secretarial Auditors and Secretarial Audit Report :

Pursuant to provisions of Section 204 of the Companies Act, 2013, the Company has appointed M/s Puttaparthi Jagannatham&Co., Company Secretaries to undertake the Secretarial Audit of the Company. The Secretarial Audit Report is annexed as Annexure-II & II -A.

The Secretarial Audit Report does not contain any qualification, reservation or adverse remarks.



Phyto Chem (India) Limited

19. Particulars of Contracts or Arrangements with Related Parties under Section 188 of the Companies Act, 2013 :

All contracts / arrangements / transactions entered by the Company during the financial year with related parties were in the ordinary course of business and on an arm's length basis. During the year, the Company has taken an Unsecured Loan(s) from Mr. Y. Nayudamma (DIN: 00377721), Managing Director and Mr. Y. Janaki Ramaiah (DIN: 06949910), Executive Director of the Company on an arm's length basis and repaid the whole amount and also the Company has paid Rs.6,38,880 towards rent for Office premises to Mr. Y. Sreemannarayana, Son of Managing Director. Disclosures as required under form AOC-2 are annexed as Annexure – III and also contained in Notes-14 & Notes-31 to Financial Statements and the Company has not entered into any other related party transactions. The Loans provided by the Directors with their own resources.

20. Disclosures under Sexual Harassment of Women at workplace (Prevention, Prohibition and Redressal) Act, 2013 :

Your Company has complied with provisions relating to the constitution of Internal Complaints Committee under the Sexual Harassment of women at workplace (Prevention, Prohibition and Redressal) Act, 2013. There are no cases filed / complaints lodged in the Company during the year under review in respect of the Sexual Harassment of Women at workplace.

21. Directors and Key Managerial Personnel:

Pursuant to provisions of Section 149 and other applicable provisions of the Companies Act, 2013 read with Rules thereon, the following Directors were appointed as Independent Directors of the Company at the 31st Annual General Meeting held on 28-12-2020 for a period of five years effective from the meeting date.

- | | | | |
|------|-------------------------|---|---------------|
| i. | Dr. G. S. R. Anjaneyulu | - | DIN: 01874325 |
| ii. | Mr. K. Ravindra Babu | - | DIN: 00328421 |
| iii. | Mr. S. Y. Sampath Kumar | - | DIN: 02389255 |
| iv. | Mrs. G. Vijitha | - | DIN: 03492979 |

In accordance with the provisions of Section 152 of the Companies Act, 2013, Mr. Anjaneyulu Prathipati (DIN: 00377635) was reappointed as Director of the Company who retires by rotation at the 31st Annual General Meeting held on 28-12-2020 and Dr. Sreemannarayana Prathipati (DIN: 00377472) will retire by rotation at this Annual General Meeting and being eligible, has offered himself for re-appointment. During the year, the Non-Executive and Independent Directors of the Company had no pecuniary relationship or transactions with the Company.

22. Declaration by the Independent Directors of the Company that they meet the criteria of independence as provided in Sec 149(6) of the Companies Act, 2013:

All the independent Directors have given declarations that they meet the requisite criteria of independence as provided in sub-section (6) of Section 149 of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

23. Formal evaluation statement by the Board of its own performance, it's committees and individual Directors :

Pursuant to the provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has formulated a policy for evaluation of its Board, Board Committees, Directors and their performances and carried out evaluation of them. The manner in which the evaluation was carried out has been explained in the Corporate Governance Report.

24. Number of Meetings of the Board :

Five meetings of the Board were held during the year. The details of the meetings of the Board are given in the Corporate Governance Report.

Phyto Chem - Annual Report - 2020-21

25. Audit Committee :

Four meetings of the Audit Committee were held during the year. The details pertaining to composition of Audit Committee are included in the Corporate Governance Report.

26. Risk Management Policy:

The Company has formulated effective risk management policy and through a Steering Committee oversees the Risk Management process including risk identification, impact assessment, effective implementation of the mitigation plans and risk reporting. The major risks identified in the Company are systematically addressed through justifying actions on a continuous basis. In addition to this, the audit committee has additional oversight in the area of financial risks and controls. The details of Risk Management as practiced by the Company is provided as part of Management Discussion and Analysis Report attached to this report.

27. Stakeholders Relationship Committee:

The Committee focuses on shareholders' grievances and strengthening of investor relations. The Committee coordinates the services of the Registrars and Share Transfer Agent and recommends measures for providing efficient services to investors. The Committee specifically looks into investor complaints like transfer/ transmission/transposition of shares and other related issues. There were no complaints pending for redressal as at 31st March 2021. The details pertaining to composition of Stakeholders Relationship Committee are given in the Corporate Governance Report.

28. Directors' Responsibility Statement:

As required under Section 134(5) of the Companies Act, 2013, with respect to Directors' Responsibility Statement, it is hereby confirmed that:

- a. In the preparation of the annual accounts for the year ended 31st March 2021, the applicable accounting standards have been followed including Ind AS Accounting Standards as notified by the Ministry of Corporate Affairs (MCA) on 16th February, 2015.
- b. The Directors have selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31st March 2021 and of the profit of the Company for the year ended on that date.
- c. The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.
- d. The Directors have prepared the annual accounts of the Company for the Financial Year ended 31st March 2021 on a going concern basis.
- e. The Directors had laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively, and
- f. The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

29. CEO and CFO Certification :

In accordance with the Regulation 17(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Managing Director (C.E.O.) and Chief Financial Officer of the Company have submitted a certificate for the year ended 31st March 2021 to the Board of Directors which forms part of the Annual Report.



Phyto Chem (India) Limited

30. Auditors & Observations:

M/s. S. T. Mohite & Co., Chartered Accountants, Hyderabad (FRN: 011410S) were appointed as Statutory Auditors of the Company for a period of five years at the 29th Annual General Meeting till the Conclusion of 34th Annual General Meeting of the Company.

The Auditors' Report for the year ended 31st March 2021 does not contain any qualification, reservation or adverse remarks on the accounts and related matters of the Company.

31. Internal Auditor:

M/s. R. B. Associates., Chartered Accountants (FRN: 009112S), Hyderabad are the Internal Auditors for the year 2020-21. They have submitted quarterly reports for the financial year 2020-21 to the Board and there are no material adverse comments.

32. Cost Accountant for Cost Accounting Records:

Pursuant to the provisions of Section 148 of the Companies Act, 2013, as amended by the Companies Amendment Act, 2017 read with Rule 6 of Companies (Cost Records and Audit) Rules, 2014, the Company has to maintain Cost Accounting Records for the financial year 2020-21. M/s. Sreshti & Associates, Cost Accountants (FRN: 100644) were appointed on the recommendation of the Audit Committee to review and certify that Cost accounting records of the Company for the financial year 2020-21.

33. Policy on Directors' Appointment and Remuneration and other details:

The Nomination and Remuneration Committee has laid down the policy for Remuneration of Directors, KMP & other Employees and the criteria has been formulated by the Committee for determining qualifications, positive attributes and independence of a Director. The Company's policy on Directors' appointment and remuneration and other matters provided in Section 178(3) of the Act has been disclosed in the Corporate Governance Report.

34. Depository System :

As the Members are aware, your Company's shares are tradable compulsorily in electronic form and your Company has established connectivity with Central Depository Services (India) Limited (CDSL) & National Securities Depository Limited (NSDL). In view of the numerous advantages offered by the depository system, the members are requested to avail the facility of Dematerialisation of the Company's shares on CDSL or NSDL. The ISIN allotted to the Company's Equity shares is **INE 037C01010**.

35. Vigil Mechanism / Whistle Blower Policy:

Pursuant to Section 177 (9) of the Companies Act, 2013 read with Rule 7 of the Companies (Meetings of Board and its Powers) Rules, 2014, the Board of Directors had approved the Policy on Vigil Mechanism / Whistle Blower and the same is posted on the official website of the Company. This Policy inter-alia provides a direct access to the Chairman of the Audit Committee.

Your Company hereby affirms that no Director / Employee has been denied access to the Chairman of the Audit Committee and that no complaints were received during the year.

36. Particulars of Employees

The Company has no employee whose remuneration falls within the purview of the limits prescribed under the provisions of Section 197 of the Companies Act, 2013, read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

Particulars of Remuneration

Disclosures with respect to the remuneration of Directors and Employees as required under Section 197(12) of Companies Act, 2013 and Rule 5 (1) Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are given below:

Phyto Chem - Annual Report - 2020-21

a. The ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year 2020-21:

i. Executive Directors:

S.No.	Executive Directors	Ratio
1.	Mr. Y. Nayudamma	16.99
2.	Mr. Y. Janaki Ramaiah	8.46

ii. Non-Executive Directors:

S.No.	Name of the Director	Ratio
1.	Dr. P. Sreemannarayana	0.12
2.	Dr. Y. Venkateswarlu (Mr. K. Srinivasa Rao - Alternate Director)	0.02
3.	Mr. P. Anjaneyulu	0.05
4.	Mr. T. A. Choudary (upto 12-11-2020)	0.12
5.	Mr. N. Sudhakar (upto 12-11-2020)	0.04
6.	Mrs. S. Kavitha Rani (upto 12-11-2020)	0.12
7.	Dr. G. S. R. Anjaneyulu	0.19
8.	Mr. M. Sree Ram Murthy	0.16
9.	Mr.K.Ravindra Babu (w.e.f. 28-12-2020)	0.12
10.	Mr. S. Y. Sampath Kumar (w.e.f. 28-12-2020)	0.12
11.	Mrs. G. Vijitha (w.e.f. 28-12-2020)	0.09

The Company has not paid any remuneration to the Non-Executive Directors except sitting fee.

b. The percentage increase in remuneration of each Director, Chief Executive Officer, Chief Financial Officer, Company Secretary in the financial year:

There is increase in remuneration of Managing Director which is 37.25% and Executive Director 21.94% which is in comparison to previous financial year.

c. Percentage increase/ (decrease) in the median remuneration of employees in the financial year: (7.81%)

d. The number of permanent employees on the rolls of Company: 85

e. The explanation on the relationship between average increase/ (decrease) in remuneration and Company performance:

The increase in remuneration is in line with market trends. As per the Company's practice, annual increments to the Employees were sanctioned and hence there was increase in the remuneration of the employees working at present.

The changes in average increase/ (decrease) of remuneration was registered on account of increased performance of employees and withdrawal of services of non performing employees during the year with no effect on current Business and turnovers.



Phyto Chem (India) Limited

- f. **Variations in the market capitalisation of the Company as at the closing date of the current financial year and previous financial year:**

Particulars	As at 31-03-2021	As at 31-03-2020
Closing rate of share at BSE (Rs.)	17.10	17.95
EPS (Rs.)	1.15	1.04
Market Capitalization (Rs in Lakhs)	735.33	771.89

- g. **Percentage increase or decrease in the market quotations of the shares of the Company in comparison to the rate at which the Company came out with the last public offer:**

The Company made an Initial Public Offer in the year 1995 at par price of Rs.10/- per each equity share. As on 31st March 2021, the Market quotation for the Company's Equity shares at BSE Limited is Rs.17.10.

- h. **Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration:**

There has been increase of 37.25% (Rs.9.50 Lakhs) of Managing Director and increase of 21.94% (Rs.3.13 Lakhs) of Executive Director in the managerial remuneration and -7.81% of decrease in the salaries to employees of the Company.

- i. **Comparison of each remuneration of the Key Managerial Personnel against the performance of the Company:**

Name of the Person	Remuneration (Rs. in Lakhs)	Total Revenue (Rs. In Lakhs)	Remuneration as a % of Revenue
Mr. Y. Nayudamma – Managing Director	35.00	4529.27	0.77
Mr. Y. Janaki Ramaiah - Executive Director	17.44	4529.27	0.39
Mr. Pavansingh Thakur - Company Secretary	6.76	4529.27	0.15
Mr. B. Sambasiva Rao - Chief Financial Officer	4.20	4529.27	0.09

- j. **The key parameters for any variable component of remuneration availed by the Directors:** Nil

- k. **The ratio of the remuneration of the highest paid Director to that of the employees who are not Directors but receive remuneration in excess of the highest paid Director during the year:** None.

- l. **Affirmation that the remuneration is as per the remuneration policy of the Company:**

The Company affirms remuneration paid to Key Managerial Personnel is as per the remuneration policy of the Company.

37. Corporate Governance :

The Company is committed to maintain and adhere to the good standards of Corporate Governance. As per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a Report on Corporate Governance forming part of this Report, together with the Auditors' Certificate regarding the compliance of the conditions of Corporate Governance is given in a separate section in the Annual Report.

Phyto Chem - Annual Report - 2020-21

38. Management Discussion and Analysis Report:

Management Discussion and Analysis Report, pursuant to Regulation 34 (2) of SEBI (LODR) Regulations, 2015 a Report on Management Discussion and Analysis is annexed hereto as Annexure - IV.

39. Particulars regarding Energy Consumption, Technology Absorption and Foreign Exchange Earning and Outgo:

The particulars prescribed under Section 134 of the Companies Act, 2013 read with Rule 8 (3) of the Companies (Accounts) Rules, 2014, relating to Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo are furnished in Annexure-V to this Report.

40. Prevention of Insider Trading :

Your Company has in place code of conduct to regulate, monitor and report trading by designated persons and code of practices and procedures for fair disclosure of unpublished price sensitive information which is in adherence to the SEBI (Prohibition of insider trading) Amendment Regulations, 2018. The disclosures received pursuant to this code and the Regulations are disseminated to the Stock Exchanges within prescribed time limit. The Report of compliance officer was placed before the Board. The code is available at the company's website at the following link www.phytochemindia.com

All the Board Members and the designated employees have confirmed the compliance with the Code.

41. Payment of Listing fee :

The shares of the Company are listed at Bombay Stock Exchange Limited, which has nation wide trading terminals and the listing fee has been paid by the Company upto date.

Acknowledgements:

The Directors wish to express their appreciation for the assistance and continued co-operation received from the Central and State Governments, Banks, Financial Institutions, Customers, Dealers and Suppliers and also the Directors wish to thank all the employees for their dedicated contribution, support and continued co-operation throughout the year at all levels.

For and on behalf of the Board

Place : Hyderabad
Date : 14th August 2021

Y.Nayudamma
Managing Director
DIN: 00377721



Phyto Chem (India) Limited

**Phyto Chem (India) Limited
Extract of Annual Return
Form No.MGT - 9**

Annexure-I

**as on the financial year ended on 31st March 2021
(Pursuant to Section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies
(Management and Administration) Rules, 2014**

1. REGISTRATION AND OTHER DETAILS

- | | |
|---|---|
| i. Company Identification Number(CIN) | L24110TG1989PLC009500 |
| ii. Registration Date | 11-01-1989 |
| iii. Name of the Company | M/s Phyto Chem (India) Limited |
| iv. Category / Sub-Category of the Company | Company Limited by shares /
Indian Non-Government Company |
| v. Address of the Registered office and
contact details | Survey No.628, Temple Street,
Bonthapally - 502313, Gummadidala Mandal,
SangareddyDistrict, Telangana State.
Tel : 08458-275236, Fax : 040-23557714
E-Mail ID : info@phytochemindia.com |
| vi. Whether Listed Company | Yes |
| vii. Name, Address and Contact details of Registrar
and Transfer Agent, if any | M/s Bigshare Services Pvt.Limited,
306, 3rd Floor, Right Wing,Amrutha Ville,
Opp : Yashoda Hospital,Raj Bhavan Road,
Somajiguda,Hyderabad - 500 082.
Phone No.040-23374967, Fax : 040-2370295
E-Mail ID : bsshyd1@bigshareonline.com |

2. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

(All the business activities contributing 10% or more of the total turnovers of the Company shall be stated)

S.No.	Name and Description of main products / services	NIC Code of the Product / Service	% to total turnover of the Company
1	Pesticides Formulations	20211	100%

3. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES: Not Applicable

Phyto Chem - Annual Report - 2020-21

4. SHAREHOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i. Category-wise Shareholding

Category of Shareholders	No. of Shares held at the beginning of the Year (As on 31 st March 2020)				No. of Shares held at the end of the Year (As on 31 st March 2021)				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
1. Indian	-	-	-	-	-	-	-	-	-
a. Individual / HUF	1728611	8682	1737293	40.400	1728611	8782	1737393	40.402	0.002
b. Central Govt.	-	-	-	-	-	-	-	-	-
c. State Govt.	-	-	-	-	-	-	-	-	-
d. Bodies Corp.	-	-	-	-	-	-	-	-	-
e. Banks / F.I.s	-	-	-	-	-	-	-	-	-
f. Any other	-	-	-	-	-	-	-	-	-
Sub Total = A - 1	1728611	8682	1737293	40.400	1728611	8782	1737393	40.402	0.002
2. Foreign									
a. Individuals (Non-Resident Individuals / Foreign Individuals)	-	-	-	-	-	-	-	-	-
b. Bodies Corporate	-	-	-	-	-	-	-	-	-
c. Institutions	-	-	-	-	-	-	-	-	-
d. any other	-	-	-	-	-	-	-	-	-
Sub Total = A - 2	-	-	-	-	-	-	-	-	-
Total Shareholding of Promoter = A - 1+2	1728611	8682	1737293	40.400	1728611	8782	1737393	40.402	0.002
B. Public Shareholding									
1. Institutions	-	-	-	-	-	-	-	-	-
a. Mutual Funds	-	8000	8000	0.190	-	8000	8000	0.190	-
b. Banks / F.I.s	-	-	-	-	-	-	-	-	-
c. Central Govt.	-	-	-	-	-	-	-	-	-
d. State Govt(s).	-	-	-	-	-	-	-	-	-
e. Venture Capital Fund	-	-	-	-	-	-	-	-	-
f. Insurance Companies	-	-	-	-	-	-	-	-	-
g. FII's	-	-	-	-	-	-	-	-	-
h. Foreign Venture Capital Funds	-	-	-	-	-	-	-	-	-
i. Others	-	-	-	-	-	-	-	-	-
Sub Total = B - 1	-	8000	8000	0.190	-	8000	8000	0.190	-
2. Non-Institutions									
a. Bodies Corp.	234530	7200	241730	5.621	227639	7200	234839	5.461	(0.160)
i. Indian	-	-	-	-	-	-	-	-	-
ii. Overseas	-	-	-	-	-	-	-	-	-
b. Individuals									
i. Individual as Shareholders holding nominal share capital upto Rs.2.00 Lakhs	1188341	695234	1883575	43.802	1200026	694434	1894460	44.055	0.253
ii. Individual as Shareholders holding nominal share capital in excess of Rs.2.00 Lakhs	270500	0	270500	6.290	283499	-	283499	6.593	0.303
c. Others (Hindu Undivided Family)	40915	0	40915	0.951	46203	-	46203	1.074	0.123
d. Non Resident Indians	46760	66400	113160	2.632	11716	66400	78116	1.817	(0.815)
e. Overseas Corporate Bodies	-	-	-	-	-	-	-	-	-
f. Foreign Nationals	-	-	-	-	-	-	-	-	-
g. Clearing Members	5027	0	5027	0.117	17690	-	17690	0.411	0.294
h. Trusts	-	-	-	-	-	-	-	-	-
i. Foreign Bodies	-	-	-	-	-	-	-	-	-
Sub Total = B - 2	1786073	768834	2554907	59.414	1786773	768034	2554807	59.412	(0.002)
Total Public Shareholding = B - 1 + 2	1786073	776834	2562907	59.604	1786773	776034	2562807	59.602	(0.002)
C. Shares held by Custodian for GDRs & ADRs									
Grand Total = (A+B+C)	3514684	785516	4300200	100.00	3515384	784816	4300200	100.00	-



Phyto Chem (India) Limited

4. ii. Shareholding of Promoters:

S. No.	Shareholder's Name	Shareholding at the beginning of the year as on 01-04-2020			Shareholding at the end of the year as on 31-03-2021			% change in share holding during the year
		No. of Shares	% of total Shares of the Company	% of Shares pledged / encumbered to total shares	No. of Shares	% of total Shares of the Company	% of Shares pledged / encumbered to total shares	
1	Mr. Y. Nayudamma	338306	7.87	-	338306	7.87	-	-
2	Mrs. U. Ramadevi	162400	3.78	-	162400	3.78	-	-
3	Dr. P. Sreemannarayana	125100	2.91	-	125100	2.91	-	-
4	Mr. Y. Janakiramaiah	97372	2.26	-	97372	2.26	-	-
5	Dr. Y. Venkateswarlu	95000	2.21	-	95000	2.21	-	-
6	Mrs. P. Akkamma	84400	1.96	-	84400	1.96	-	-
7	Mrs. M. Nagendram	75800	1.76	-	75800	1.76	-	-
8	Mr. P. Nagaraja	70500	1.64	-	70500	1.64	-	-
9	Mr. Y. Prabhakara Rao	65200	1.52	-	65200	1.52	-	-
10	Mr. P. Anjaneyulu	64400	1.50	-	64400	1.50	-	-
11	Mrs. Y. Lakshmi Prasanna	55078	1.28	-	55078	1.28	-	-
12	Mrs. A. Ranga kumari	46000	1.07	-	46000	1.07	-	-
13	Mrs. T. Rajanee Devi	40500	0.94	-	40500	0.94	-	-
14	Mrs. J. Anjana Devi	39700	0.92	-	39700	0.92	-	-
15	Mrs. K. Subhashini	32700	0.76	-	32700	0.76	-	-
16	Mr. Y. Sreemannarayana	102011	2.37	-	102011	2.37	-	-
17	Mrs. M. Sreelakshmi Bhavani	32500	0.76	-	32500	0.76	-	-
18	Mrs. P. Umadevi	31000	0.72	-	31000	0.72	-	-
19	Mrs. Y. Nirmala Devi	30000	0.70	-	30000	0.70	-	-
20	Mr. K. R. Choudary	26300	0.61	-	26300	0.61	-	-
21	Mr. K. Srinivasa Rao	19994	0.465	-	20094	0.467	-	0.002
22	Mrs. K. Lakshmi Devi	18300	0.43	-	18300	0.43	-	-
23	Mr. Y. Anil Choudary	17600	0.41	-	17600	0.41	-	-
24	Mr. Y. Venkateswarlu	14400	0.33	-	14400	0.33	-	-
25	Mrs. R. Jyotsna	12500	0.29	-	12500	0.29	-	-
26	Mrs. K. Ramasasi	11990	0.28	-	11990	0.28	-	-
27	Mr. K. Koteswara Rao	8300	0.19	-	8300	0.19	-	-
28	Mrs. R. Vijaya Sasi	8176	0.19	-	8176	0.19	-	-
29	Mr. T. Venkateswarlu	8000	0.19	-	8000	0.19	-	-
30	Mr. P. Nageswara Rao	2500	0.06	-	2500	0.06	-	-
31	Mr. U. Venkateswara Rao	900	0.02	-	900	0.02	-	-
32	Mr. B. Srinivasa Rao	182	0.004	-	182	0.004	-	-
33	Mr. C. N. Chary	100	0.002	-	100	0.002	-	-
34	Mr. T. Ankamma Choudary	84	0.002	-	84	0.002	-	-
	TOTAL	1737293	40.400	-	1737393	40.402	-	0.002

Phyto Chem - Annual Report - 2020-21

4. iii. Change in Promoters' Shareholding (please specify, if there is no change)

S.No.	Particulars	Shareholding at the beginning of the year as on 01-04-2020		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the Company	No. of shares	% of total shares of the Company
1	At the beginning of the year date wise Increase / Decrease in	1737293	40.400	1737293	40.400
2	Promoters: a. Increase by transfer b. Decrease by transfer	100 -	0.002 -	1737393 -	40.402 -
3	At the end of the year - 31-03-2021	1737393	40.402	1737393	40.402

4. iv. Shareholding Pattern of top ten Shareholders: (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.	For each of the Top 10 Shareholders	Shareholding at the beginning of the year 01-04-2020		Shareholding at the end of the year 31-03-2021	
		No. of Shares	% of total Shares of the Company	No. of Shares	% of total Shares of the Company
1	Andhra Pradesh Industrial Development Corporation Limited	199000	4.63	199000	4.63
2	Mrs. Anitha Gupta	124359	2.89	111071	2.58
3	Mrs. P. Himabindu	38021	0.88	38021	0.88
4	Mr. Rasilaben Dipakbhai Gaudani	29626	0.69	34926	0.81
5	Mr. Kashyap Mukeshbhai Prajapati	31933	0.74	31933	0.74
6	Mr. Heena Jayesh Patel	25461	0.59	25461	0.59
7	Mr. Bhaskar R. Ravi	24000	0.56	24000	0.56
8	Mr. Mohineesh Yalamanchili	21100	0.49	21100	0.49
9	Mr. Jigarkumar Subhashchandra Shah	18506	0.43	18505	0.43
10	Mr. Shobhaben Purshottamdas Sarpa	7500	0.17	17521	0.41



Phyto Chem (India) Limited

4. v. Shareholding of the Directors and Key Managerial Personnel:

S. NO.	Shareholding of each Director and each Key Managerial Personnel	Shareholding at the beginning of the year 01-04-2020		Cumulative shareholding during the year	
		No. of shares	% of total shares of the Company	No. of shares	% of total shares of the Company
1	Dr. P. Sreemannarayana				
	a. At the beginning of the year	125100	2.91	125100	2.91
	b. Date wise Increase/Decrease	-	-	-	-
	c. At the end of the year	125100	2.91	125100	2.91
2	Mr. Y. Nayudamma				
	a. At the beginning of the year	338306	7.87	338306	7.87
	b. Date wise Increase/Decrease	-	-	-	-
	c. At the End of the year	338306	7.87	338306	7.87
3	Mr. Y. Janaki Ramaiah				
	a. At the beginning of the year	97372	2.26	97372	2.26
	b. Date wise Increase/Decrease	-	-	-	-
	c. At the end of the year	97372	2.26	97372	2.26
4	Mr. P. Anjaneyulu				
	a. At the beginning of the year	64400	1.50	64400	1.50
	b. Date wise Increase/Decrease	-	-	-	-
	c. At the end of the year	64400	1.50	64400	1.50
5	Dr. Y. Venkateswarlu				
	a. At the beginning of the year	95000	2.21	95000	2.21
	b. Date wise Increase/Decrease	-	-	-	-
	c. At the end of the year	95000	2.21	95000	2.21
6	Mr. T. A. Choudary (upto 12-11-2020)				
	a. At the beginning of the year	84	0.002	84	0.002
	b. Date wise Increase/Decrease	-	-	-	-
	c. At the end of the year	84	0.002	84	0.002
7	Mr. N. Sudhakar (upto 12-11-2020)				
	a. At the beginning of the year	-	-	-	-
	b. Date wise Increase/Decrease	-	-	-	-
	c. At the end of the year	-	-	-	-
8	Mrs. S. Kavitha Rani (upto 12-11-2020)				
	a. At the beginning of the year	-	-	-	-
	b. Date wise Increase/Decrease	-	-	-	-
	c. At the end of the year	-	-	-	-
9	Mr. G. S. R. Anjaneyulu				
	a. At the beginning of the year	-	-	-	-
	b. Date wise Increase/Decrease	-	-	-	-
	c. At the end of the year	-	-	-	-
10	Mr. M. Sree Ram Murthy				
	a. At the beginning of the year	-	-	-	-
	b. Date wise Increase/Decrease	-	-	-	-
	c. At the end of the year	-	-	-	-
11	Mr. K. Ravindra Babu (w.e.f. 28-12-2020)				
	a. At the beginning of the year	-	-	-	-
	b. Date wise Increase/Decrease	-	-	-	-
	c. At the end of the year	-	-	-	-
12	Mr. S. Y. Sampath Kumar (w.e.f. 28-12-2020)				
	a. At the beginning of the year	-	-	-	-
	b. Date wise Increase/Decrease	-	-	-	-
	c. At the end of the year	-	-	-	-
13	Mrs. G. Vijitha (w.e.f. 28-12-2020)				
	a. At the beginning of the year	-	-	-	-
	b. Date wise Increase/Decrease	-	-	-	-
	c. At the end of the year	-	-	-	-
14	Mr. Pavansingh Thakur				
	a. At the beginning of the year	-	-	-	-
	b. Date wise Increase/Decrease	-	-	-	-
	c. At the end of the year	-	-	-	-
15	Mr. B. Sambasiva Rao				
	a. At the beginning of the year	15700	0.37	15700	0.37
	b. Date wise Increase/Decrease	-	-	-	-
	c. At the end of the year	15700	0.37	15700	0.37

Phyto Chem - Annual Report - 2020-21

5. INDEBTEDNESS:

(in Rs.)

Particulars	Secured Loans excluding Deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year (01-04-2020)				
i. Principal Amount	198841062	19611071	-	218452133
ii. Interest due but not paid	-	-	-	-
iii. Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	198841062	19611071	-	218452133
Change in Indebtedness during the financial year - 2020-21				
* Addition	6004226	-	-	6004226
* Reduction	-	(19611071)	-	(19611071)
Net Change	6004226	(19611071)		(13606845)
Indebtedness at the end of the financial year (31-03-2021)				
i. Principal Amount	204845288	-	-	204845288
ii. Interest due but not paid	-	-	-	-
iii. Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	204845288	-	-	204845288

6. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:

A. Remuneration to Managing Director, Whole-Time Directors and/ or Manager:

S.No.	Particulars of Remuneration	Name of MD/WTD/Manager		Total Amount (in Rs.)
		* Y.Nayudamma Managing Director	* Y.Janaki Ramaiah Executive Director	
1	Gross Salary			
	a. Salary as per provisions contained in section 17(1) of the Income -Tax Act, 1961	34,99,920	17,43,703	52,43,623
	b. Value of perquisites u/s 17(2) Income -Tax Act, 1961	---	---	---
	c. Profits in lieu of Salary under section 17(3) Income - Tax Act, 1961	---	---	---
2	Stock Option	---	---	---
3	Sweat Equity		-	-
4	Commission -as % of profit -others, specify...	---	---	---
5	Others, please specify	---	---	---
	Total -A	34,99,920	17,43,703	52,43,623
	Ceiling as per the Act	Rs. 84,00,000 p.a.	Rs. 84,00,000 p.a.	-



Phyto Chem (India) Limited

6. B. Remuneration to other Directors :

(in.Rs.)

Sl. No.	Name of the Director	Particulars of Remuneration			
		Fee for attending Board, Committeemeetings	Commission	Others, please specify	Total Amount
I	Independent Directors				
1	Mr. T. A. Choudary**	24,000	-	-	24,000
2	Mr. N. Sudhakar**	8,000	-	-	8,000
3	Mrs. S. Kavitha Rani**	24,000	-	-	24,000
4	Dr. G. S. R. Anjaneyulu	40,000	-	-	40,000
5	Mr. M. Sree Ram Murthy	32,000	-	-	32,000
6	Mr. K. Ravindra Babu**	24,000	-	-	24,000
7	Mr. S. Y. Sampath Kumar**	24,000	-	-	24,000
8	Mrs. G. Vijitha**	19,000	-	-	19,000
	Total - I	195,000	-	-	195,000
II	Other Non-Executive Directors				
1	Mr. P. Sreemannarayana	25,000	-	-	25,000
2	Mr. P. Anjaneyulu	10,000	-	-	10,000
3	Dr. Y. Venkateswarlu	-	-	-	-
4	Mr. K. Srinivasa Rao - Alternate Director	5,000	-	-	5,000
	Total - II	40,000	-	-	40,000
	Total - B (I+II)	235,000	-	-	235,000
Overall ceiling for Sitting fee as per the Act		Not exceeding Rs. 1.00 lakh each meeting per member			
Total Managerial Remuneration (A+B)					5,478,623

6. C. Remuneration to Key Managerial Personnel otherthan MD/WTD/Manager

in.Rs.

S.N	Particulars of Remuneration	Key Managerial Personnel			
		CEO	CFO	CS	Total
1	Gross Salary				
a.	Salary as per provisions Contained in Section 17(1) of the Income-tax Act, 1961	-	419,796	675,909	1,095,705
b.	Value of perquisites u/s 17(2) Income-tax Act, 1961	-	-	-	-
c.	Profits in lieu of salary under section17(3) Income-tax Act, 1961	-	-	-	-
2	Stock Option	-	-	-	-
3	Sweat Equity	-	-	-	-
4	Commission	-	-	-	-
	- as % of profit	-	-	-	-
	- others, specify	-	-	-	-
5	Others, please specify	-	-	-	-
	Total	-	419,796	675,909	1,095,705

Note:

* Mr. Y. Nayudamma is the Managing Director as well as CEO of the Company and his remuneration particulars are given in Table 6.A. above and Remuneration Particulars of Mr. Y. Janaki Ramaiah, Executive Director are also given in Table 6.A. above.

** Mr. K. Ravindra Babu, Mr. S. Y. Sampath Kumar and Mrs. G. Vijitha were appointed as Independent Directors of the Company w.e.f. 28-12-2020 in the vacancies caused on completion of 2 Consecutive terms by Mr. T. A. Choudary, Mr. N. Sudhakar and Mrs. S. Kavitha Rani as Independent Director of the Company on 12-11-2020.

7. PENALTIES / PUNISHMENTS / COMPOUNDING OF OFFENCES: None

Phyto Chem - Annual Report - 2020-21

Secretarial Audit Report

Annexure - II

Form No. MR-3

for the Financial Year ended on 31st March 2021

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To

The Members,

M/s Phyto Chem (India) Limited,

Survey No. 628, Temple Street,

Bonthapally - 502 313,

Gumadidala Mandal, Sangareddy District,

Telangana State.

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **M/s Phyto Chem (India) Limited (CIN: L24110TG1989PLC009500)** (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, We hereby report that in our opinion, the company has, during the audit period covering the financial year ended on 31st March, 2021 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by Phyto Chem (India) Limited ("the company") for the financial year ended on 31st March, 2021 according to the provisions of:

- I. The Companies Act, 2013 (the Act) and the rules made thereunder;
- II. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- III. The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- IV. Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- V. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act') :-
 - a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - c. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
 - d. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009;
 - e. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulation, 2014;
 - f. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008;
 - g. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009;
 - h. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998;
 - i. The Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015



Phyto Chem (India) Limited

VI. and other specific laws applicable to the Company

- i. Insecticides Act, 1968
- ii. Legal Metrology Act, 2009
- iii. The Petroleum Rules 2002

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India with respect to the Board and General Meeting.
- (ii) The Listing Agreements entered into by the Company read with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (to the extent applicable).

We further report that

- (i) based on the information provided by the Company, its officers and its authorised representatives during the conduct of the audit and also on review of quarterly reports by respective Department Heads/Company Secretary/ CEO taken on record by the Board of Directors of the Company, adequate systems and processes and control mechanism exist in the company to monitor and ensure the compliance of with the applicable general laws like labour laws, competition law and environment laws.
- (ii) the Compliance by the Company of applicable financial laws like direct and indirect laws has not been reviewed in this Audit since the same have been subject to review by Statutory Financial Audit and Other designated professionals.
- (iii) the Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors.
- (iv) adequate notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.
- (v) all the decisions at the Board Meetings and Committee Meetings have been carried out unanimously as recorded in the Minutes of the meetings of the Board of Directors or Committee of the Board, as the case may be.

We further report that, during the period covered under audit, two forms were filed late with additional fee with the Registrar of Companies. However, the Compliance has been met by the Company. We further report that

- (i) there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.
- (ii) there were no specific events/actions in pursuance of the above referred laws, rules, regulations, etc., having a major bearing on the Company's affairs except as reported in the Financial Audit Report:

For Puttaparthi Jagannatham & Co.

**Navajyoth Puttaparthi
Partner**

**Place : Hyderabad
Date : 12th August 2021**

**FCS No: 9896; C P No.: 16041
UDIN: F009896C000775133**

Note: This report is to be read with our letter of even date which is annexed as "Annexure" and forms integral part of this report.

Phyto Chem - Annual Report - 2020-21

Secretarial Audit Report

Annexure: II-A

To
The Members,
M/s Phyto Chem (India) Limited,
Survey No.628, Temple Street,
Bonthapally - 502 313,
Gummadidala Mandal, Sangareddy District,
Telangana State.

Our report of event date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of accounts of the company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

For Puttaparthi Jagannatham & Co.

Navajyoth Puttaparthi
Partner

FCS No: 9896; C P No.: 16041
UDIN: F009896C000775133

Place : Hyderabad
Date : 12th August 2021



Phyto Chem (India) Limited

Annexure – III

FORM NO. AOC – 2

[Pursuant to clause (h) of sub-section (3) of section 134 of the Companies Act, 2013 and Rule 8 (2) of the Companies (Accounts) Rules, 2014]

Form for Disclosure of particulars of Contracts / Arrangements entered into by the Company with the related parties referred to in Section 188 of the Companies Act, 2013.

1. Details of contracts or arrangements or transactions not at arm's length basis: Nil
2. Details of material contracts or arrangements or transactions at arm's length basis:

Name(s) of the related party and nature of relationship	Nature of contracts/ arrangements/ transactions	Duration of the contracts/ arrangements/ transactions	Salient terms of the contracts or arrangements or transactions including the value, if any	Dates of approval by the Board, if any	Amount in Rs.
Mr. Y. Nayudamma Managing Director	Unsecured Loan	On demand	Repayable with interest	20-07-2019	-
Mr. Y. Janaki Ramaiah Executive Director	Unsecured Loan	On demand	Repayable with interest	20-07-2019	-

Phyto Chem - Annual Report - 2020-21

Annexure – IV

Management Discussion and Analysis

M/s Phyto Chem (India) Limited has been carrying on the business predominantly in two segments i.e. Pesticides Formulations and Real Estate activities and the Company has recently launched into trading of frozen Green Peas business under its experimental Food Division and expecting progress in the front.

As we are aware, the Pesticides play a vital role in Agriculture and has been consistently contributing to the agricultural growth of the Agriculture Sector year on year for over decades. The Manufacturing facility in the Company for pesticides formulations are producing good quality products and they have been contributing to the top line of the company even in testing times in Agriculture. The Real Estate activity holding good promise and the company plans to embark on bigger plans during the current and future years and the Company will unveil its plans for excellence. The company is positive of proposed Food Division business and expects to register good progress on the back of increased awareness of the foods that contribute to the immunity and health of the public amidst Covid19 times.

The SWOT Analysis is as follows:

1. Strengths:

- The Company established its Brand for quality, customized marketing approach. Encouraging Government policies and increased irrigation facilities in the country are positive factors.
- Positive growth in Real Estate and Infrastructure sectors in the country and good opportunities in the Food Division are holding promise.

2. Weakness:

- Untimely rainfall & un-favorable climatic conditions are cause of concern competition from the big players through their trade practices and irregular and unexpected changes. Of course the sail into food division is also fraught with the competition from the existing players.
- Inflation related Economy, Natural calamities and Oscillations in demand for Real Estate related projects.

3. Opportunities:

- Encouraging policies of the Government in Agriculture Sector and increase in the product range and newer markets.
- Government policies and enhanced purchasing power is auguring well for good demand in the Real Estate.
- Food business market would benefit the company for good.

4. Threats:

- Competition from big players, unorganized quality agencies, Change in Government policies and Bank interest rates have bearing.
- Increased prices, income tax structure and interest rates have bearing on the demand for Real Estate activities. Price wars are common from big players and other competitors in the market.
- Covid-19 has all pervasive negative sentiment and had caused effect in realisation of returns from the pesticides market, and also on opportunities in the Real Estate and Food business.

5. Financial Analysis:

The Financial Analysis of the Company have been detailed in Directors' Report under para Review of Operations.

6. Future Outlook:

- The Company tries to continue its focus on product and its quality development and also to penetrate into key markets.
- Company exploring new opportunities for diversification and expansion into new business areas like Food business, construction activities etc.

7. Internal Control Procedures:

The Company has Audit Committee and has the mechanism to review the Internal Audit Control procedures. Periodic Audits of the Accounts are carried out internally to attain the object of internal procedures. The Company has also appointed M/s R.B.Associates., Chartered Accountants as Internal Auditors of the Company to conduct internal audit on the Accounts and procedural Compliances.

8. Human Resources:

The Company has able and experienced staff and dedicated executives. The human relations with the staff continue to be good. In house training is given to the employees to motivate and contribute to the enhanced productivity. The human resources are considered invaluable resources of the Company.

9. Cautionary Statement:

The statements in the Management Discussion and Analysis describing the Company's objectives, projections, estimates or expectations may be "forward-looking" statements within the meaning of applicable Securities, Laws and Regulations. Actual results could differ materially from those expressed or implied and the achievement of results is subject to risks, uncertainties, economic conditions, demand / supply, price conditions and impact of Covid-19 which may influence the operations of the Company.

For and on behalf of the Board

Place : Hyderabad
Date : 14th August 2021

Y.Nayudamma
Managing Director
DIN: 00377721



Phyto Chem (India) Limited

Annexure – V

Conservation of Energy, Technology Absorption, Foreign Exchange and Outgo. Information under Section 134 of the Companies Act, 2013 read with rule 8 of the Companies (Accounts) Rules, 2014 and forming part of Board's Report for the year ended 31st March 2021.

A. Conservation of Energy:

The Company has been putting regular efforts to improve Energy efficiency through Energy Conservation Measures.

i. Energy conservation measures taken:

- * The Company has carried out various measures to optimize energy consumption.
- * The Company has replaced conventional electrical cables, MCBs etc. with latest Electrical items.

ii. Impact of measures taken:

- * Reduction in annual diesel oil consumption.
- * Continuous alertness of power saving.

iii. Steps taken for utilizing alternate sources of the energy:

- * Company is evaluating the economic viability for installation of Solar Street Lights and Solar panels for Plant Lighting.

iv. Capital investment on Energy conservation equipments:

- * Capital Expenditure has not been accounted for separately.

B. Technology Absorption:

Research and Development (R&D):

i. Effects in brief made towards Technology Absorption:

- * The Company has adopted Indigenous Technology for manufacture of Pesticides Formulations and no imported technology is involved.
- * The Company has an In-house R&D division for improving the quality, productivity and for developing the new viable products.

ii. Benefits derived as a result of the above efforts:

- * Improvement in product quality and productivity.
- * Enhanced products range to address emerging market opportunities.

iii. Imported technology (imported during the last three years reckoned from the beginning of the financial year):

- * Not applicable as no technology was imported during the last three years.

iv. Expenditure incurred on Research and Development:

- * R & D Expenditure has not been accounted for separately.

C. Foreign Exchange Earnings and Outgo:

During the year, there were no exports. The export market for pesticide formulations is not encouraging due to thin margins and heavy competition from Technical Pesticide Manufacturers.

i. Total Foreign Exchange outflow:

Equivalent to Rs.185.04 lakhs (USD 2.485 lakhs) towards Raw materials.

ii. Total Foreign Exchange inflow:

Equivalent to Rs. Nil (USD Nil) towards Exports of Pesticides Formulations.

For and on behalf of the Board

Place : Hyderabad
Date : 14th August 2021

Y.Nayudamma
Managing Director
DIN: 00377721

Phyto Chem - Annual Report - 2020-21

Corporate Governance Report

1. Company's Philosophy on Corporate Governance:

The Board lays strong emphasis on attainment of high levels of Transparency, Accountability and Integrity and the corporate actions, which balance the interest of the stakeholders. The Company has adopted a code of conduct for Members of the Board, Senior Management and Key Managerial Personnel, who have all affirmed in writing their adherence to the Code.

2. Board of Directors:

The Board of Directors comprises of 10 Directors of which 3 are Promoter Directors. viz. Dr. P. Sreemannarayana, Mr. Y. Nayudamma and Dr. Y. Venkateswarlu. Five Board Meetings were held during the period from April 2020 to March 2021 on the following dates:

29th June 2020, 14th September 2020, 12th November 2020, 28th December 2020, and 12th February 2021.

The Attendance of the Directors at Meetings and Number of other Directorships:

Sl. No.	Name of the Director	Designation	Category	Number of Board Meetings attended	Attendance at last AGM (Yes/No)	Other Directorships
1.	Dr. P. Sreemannarayana	Chairman	NE & NI	5	Yes	2
2.	Mr. Y. Nayudamma	M.D	E & NI	5	Yes	4
3.	Mr. Y. Janaki Ramaiah	E.D	E & NI	5	Yes	1
4.	Dr. Y. Venkateswarlu	Director	NE & NI	-	No	-
	a. Mr. K. Srinivasa Rao	Alternate Director	NE & NI	1	No	1
5.	Mr. P. Anjaneyulu	Director	NE & NI	2	No	3
6.	Mr. T.A. Choudary (upto 12-11-2020)	Director	NE & I	3	NA	-
7.	Mr. N. Sudhakar (upto 12-11-2020)	Director	NE & I	1	NA	-
8.	Mrs. S. Kavitha Rani (upto 12-11-2020)	Director	NE & I	3	NA	-
9.	Dr. G.S.R. Anjaneyulu	Director	NE & I	5	Yes	-
10.	Mr. M. Sree Ram Murthy	Director	NE & I	4	Yes	3
11.	Mr. K. Ravindra Babu (w.e.f. 28-12-2020)	Director	NE & I	2	Yes	1
12.	Mr. S.Y. Sampat Kumar (w.e.f. 28-12-2020)	Director	NE & I	2	Yes	4
13.	Mrs. G. Vijitha (w.e.f. 28-12-2020)	Director	NE & I	1	No	2

NE = Non-Executive I = Independent E = Executive NI = Non - Independent

None of the Directors on the Board is a member of more than 10 Committees and Chairman of more than 5 Committees across all the Companies in which they are Directors.

3. Code of Conduct:

Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has suitably modified the 'Code of Conduct for Board of Directors, Senior Management and Key Managerial Personnel' (Code of Conduct) and is available on the Company's website. The Directors, Key Managerial Personnel and Senior Management Personnel have affirmed their compliance with the Code of Conduct as at 31st March 2021.



Phyto Chem (India) Limited

4. Audit Committee:

The Company has a qualified and independent Audit Committee comprising five non-executive Independent Directors, constituted in accordance with the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 entered with the Stock Exchange and Section 177 of the Companies Act, 2013. The role, terms of reference, authority and powers of the Audit Committee are in conformity with the requirements of Companies Act, 2013 and Listing Agreement.

The Committee held Four meetings during the year 2020-21 i.e. on 29th June 2020, 14th September 2020, 12th November 2020 and 12th February 2021 and the attendance at the meetings was as under:

S.No.	Name of the Member	Attendance Particulars	Category
1.	Dr. G. S. R. Anjaneyulu	4	Chairman
2.	Mr. N. Sudhakar (upto 12-11-2020)	1	Member
3.	Mr. T. A. Choudary (upto 12-11-2020)	3	Member
4.	Mrs. S. Kavitha Rani (upto 12-11-2020)	3	Member
5.	Mr. M. Sree Ram Murthy	3	Member
6.	Mr. K. Ravindra Babu (w.e.f. 28-12-2020)	1	Member
7.	Mr. S. Y. Sampat Kumar (w.e.f. 28-12-2020)	1	Member
8.	Mrs. G. Vijitha (w.e.f. 28-12-2020)	1	Member

The Audit Committee discussed with the Statutory Auditors on the "Limited Review" of the quarterly / half-yearly / yearly accounts, the audit plan for the year, matters relating to compliance with accounting standards, the Auditors observations arising from the Annual Audit of the Company's accounts and other related matters. Mr. G. S. R. Anjaneyulu, Chairman, Audit Committee was present in the last Annual General Meeting.

5. Nomination and Remuneration Committee:

The Nomination and Remuneration Committee held two meetings during the year 2020-21 i.e., 14th September 2020 and 12th November 2020 with the following members :

Sl.No	Name of the Member	Attendance	Category
1.	Mr. M. Sree Ram Murthy	1	Chairman
2.	Mr. T. A. Choudary (upto 12-11-2020)	2	Member
3.	Mr. N. Sudhakar (upto 12-11-2020)	-	Member
4.	Mrs. S. Kavitha Rani (upto 12-11-2020)	2	Member
5.	Dr. G.S.R. Anjaneyulu	2	Member
6.	Mr. K. Ravindra Babu (w.e.f. 28-12-2020)	-	Member
7.	Mr. S. Y. Sampat Kumar (w.e.f. 28-12-2020)	-	Member
8.	Mrs. G. Vijitha (w.e.f. 28-12-2020)	-	Member

Remuneration Policy:

Remuneration Policy of the Company is summarised as follows:

a. Policy for Selection and Appointment of Directors and their Remuneration:

The Remuneration Committee has adopted a Charter which, inter-alia, deals with the manner of selection of Board of Directors and Executive Directors and their remuneration.

b. Criteria of Selection of Non Executive Directors:

The Non-Executive Directors shall be of high integrity with relevant expertise and experience so as to have a diverse Board with Directors having expertise in the fields of manufacturing, marketing, finance, taxation, laws, governance and general management.

Phyto Chem - Annual Report - 2020-21

In case of appointment of Independent Directors, the Remuneration Committee shall satisfy itself with regard to the independent nature of the Directors vis-à-vis the Company so as to enable the Board to discharge its functions and duties effectively.

The Remuneration Committee shall ensure that the candidate identified for appointment as a Director is not disqualified for appointment under Section 164 of the Companies Act, 2013. The Remuneration Committee shall consider the following attributes / criteria, whilst recommending to the Board the candidature for appointment as Director.

- i. Qualification, expertise and experience of the Directors in their respective fields;
- ii. Personal, Professional or business standing;
- iii. Diversity of the Board.

In case of reappointment of Non Executive Directors, the Board shall take into consideration the performance evaluation of the Director and his engagement level.

c. Remuneration:

i. For Managing Director and Executive Director:

The total remuneration payable to Managing Director and Executive Director is subject to Shareholders' approval and consists of Salary, Allowances, Perquisites and Benefits are in line with the Company's rules for Senior Managerial Personnel and Key Managerial Personnel.

ii. For Non-Executive Directors:

Sitting Fees is paid as per applicable provisions of the Companies Act, 2013 and rules made thereunder and the Articles of Association of the Company for attending meetings of the Board or any committees of the Board. The Directors are also reimbursed actual travel costs & incidental expenses incurred for attending such meetings or in connection with the Company's business. The Chairman of the Company is reimbursed the cost of travel and expenses incurred for attending Board and General Meetings.

The details of Remuneration of Directors during the period under review are as follows:

Sl. No.	Name of the Director	Relationship with other Directors	Sitting Fees Rs.	Commission on Profits Rs.	Salary & Allowances Rs.	Perquisites Rs.	Total Rs.
1.	Dr. P. Sreemannarayana	Relative	25000.00	—	—	—	25000.00
2.	Mr. Y. Nayudamma	Relative	—	—	3499920.00	—	3499920.00
3.	Mr. Y. Janaki Ramaiah	Relative	—	—	1743703.00	—	1743703.00
4.	Mr. P. Anjaneyulu	Relative	10000.00	—	—	—	10000.00
5.	Dr. Y. Venkateswarlu	Relative	—	—	—	—	—
	a. Mr. K. Srinivasa Rao	Relative	5000.00	—	—	—	5000.00
6.	Mr. T.A. Choudary (upto 12-11-2020)	—	24000.00	—	—	—	24000.00
7.	Mr. N. Sudhakar (upto 12-11-2020)	—	8000.00	—	—	—	8000.00
8.	Mrs. S. Kavitha Rani (upto 12-11-2020)	—	24000.00	—	—	—	24000.00
9.	Dr. G. S. R. Anjaneyulu	—	40000.00	—	—	—	40000.00
10.	Mr. M. Sree Ram Murthy	—	32000.00	—	—	—	32000.00
11.	Mr. K. Ravindra Babu (w.e.f. 28-12-2020)	—	24000.00	—	—	—	24000.00
12.	Mr. S. Y. Sampath Kumar (w.e.f. 28-12-2020)	—	24000.00	—	—	—	24000.00
13.	Mrs. G. Vijitha (w.e.f. 28-12-2020)	—	19000.00	—	—	—	19000.00



Phyto Chem (India) Limited

Sitting fee to Non-executive Directors is Rs.5,000/- for each Board meeting, Rs.1500/- for each Audit Committee, Nomination and Remuneration Committee, Performance Evaluation Committee, Risk Management Committee, Stakeholders Relationship Committee, Independent Directors Committee and Share Transfer Committee meetings.

6. Performance Evaluation Committee:

The Performance Evaluation Committee met once on 12th February 2021 during the year 2020-21. The attendance record of the members at the meeting was as follows:

Sl.No.	Name of the Member	Attendance	Category
1	Mr. K. Ravindra Babu (w.e.f. 28-12-2020)	1	Chairman
2.	Dr. G.S.R. Anjaneyulu	1	Member
3.	Mr. M. Sree Ram Murthy	1	Member
4.	Mrs. G. Vijitha (w.e.f. 28-12-2020)	1	Member
5.	Mr. S.M. Sampath Kumar (w.e.f. 28-12-2020)	1	Member

7. Risk Management Committee:

The Risk Management Committee met once on 12th February 2021 during the year 2020-21. The attendance record of the members at the meeting was as follows:

Sl.No.	Name of the Member	Attendance	Designation
1.	Mr. Y. Nayudamma	1	Chairman
2.	Dr. G.S.R. Anjaneyulu	1	Member
3.	Mr. M. Sree Ram Murthy	1	Member
4.	Mr. K. Ravindra Babu (w.e.f. 28-12-2020)	1	Member
5.	Mrs. G. Vijitha (w.e.f. 28-12-2020)	1	Member
6.	Mr. S.Y. Sampath Kumar (w.e.f. 28-12-2020)	1	Member

Business Risk and Management is ongoing process within the Organization. The Company has proper risk management framework to identify, monitor and minimise risks and also identify business opportunities.

The objectives and scope of the Risk Management Committee broadly comprises of:

- Oversight of risk management performed by the Executive Management;
- Reviewing the Business Risk and Management Policy and framework in line with local legal requirements and SEBI guidelines;
- Reviewing risks and evaluate treatment including initiating mitigation actions and ownership as per a predefined cycle;
- Defining framework for identification, assessment, monitoring, mitigation and reporting of risks; within its overall scope as aforesaid, the Committee shall review risks, trends, exposure and potential impact analysis and mitigation plan.

8. Independent Directors' Committee Meeting:

During the year under review, the Committee comprises of Mr. S. Y. Sampath Kumar (w.e.f. 28-12-2020) as Chairperson, Dr. G. S. R. Anjaneyulu, Mr. M. Sree Ram Murthy, Mr. K. Ravindra Babu (w.e.f. 28-12-2020) and Mrs. G. Vijitha (w.e.f. 28-12-2020) as its members. All the members met once on 12th February 2021 inter-alia, to discuss the following items of business:

- Evaluation of the performance of the Non - Independent Directors and the Board of Directors as a whole.
- Evaluation of the performance of the Chairman of the Company taking into account the views of the Executive and Non Executive Directors;
- Evaluation of the quality, contents and timelines of flow of information between the Management and the Board that is necessary for the Board to effectively and reasonably perform its duties.

Phyto Chem - Annual Report - 2020-21

9. a. Stakeholders Relationship Committee:

The Stakeholders Relationship Committee comprises of Dr. G. S. R. Anjaneyulu as Chairman, Mr. T. A. Choudary (upto 12-11-2020), Mr. N. Sudhakar (upto 12-11-2020), Mrs. S. Kavitha Rani (upto 12-11-2020), Mr. Y. Nayudamma, and Mr. M. Sree Ram Murthy as its Members. All the Committee met once on 29th June 2020 during the year 2020-21.

All the complaints were redressed and no complaints received during the year were pending either in the beginning or ending of the year. The details are given below:

Sl. No.	Nature of Complaints.	No. of Letters received	No. of Letters resolved / replied	Pending / remarks
1.	No. of requests for Change of Address	0	0	0
2.	Non-receipt of Share Certs./ Bonus Shares	0	0	0
3.	Issue of Duplicate Share Certificates	3	3	0
4.	Non-receipt of Demat Confirmations / Rejections	0	0	0
5.	Revalidation of Refund Orders/ Dividend Warrants	0	0	0
6.	Non - receipt of Dividend Warrants	0	0	0
7.	Other Letters	7	7	0

During the year, there are no other investors' grievances pending in respect of transfers, letters from SEBI & Stock Exchange.

b. Share Transfer Committee:

The Share Transfer Committee comprises of Mr. Y. Nayudamma as Chairman, Mr. Y. Janaki Ramaiah as Convenor, Mr. B. Sambasiva Rao as Member, and Mr. Pavansingh Thakur as Compliance Officer.

10. General Body Meetings:

The last three Annual General Meetings of the Company were held at the Registered Office of the Company at Survey No.628, Temple Street, Bonthapally- 502313, Gummadidala Mandal, Sangareddy District, Telangana State.

- i. 29th September 2018 at 12:15 P.M
- ii. 25th September 2019 at 12:15 P.M
- iii. 28th December 2020 at 11:45 A.M. respectively

No postal ballots were used / invited for voting at these meetings in respect of the Special Resolutions required to be passed nor they are proposed at the ensuing Annual General Meeting.

11. Dematerialisation of Shares and Liquidity:

As on 31st March 2021, 81.75% of the shares of your Company have been dematerialised. As the trading of/ transfer of your Company shares are being conducted only in electronic form and all other members holding shares in physical form are requested to convert their shareholdings to electronic form at the earliest.

12. Disclosures under Sexual Harassment of Women at workplace (Prevention, Prohibition and Redressal) Act, 2013:

Your Company has complied with provisions relating to the constitution of Internal Complaints Committee under the Sexual Harassment of women at workplace (Prevention, Prohibition and Redressal) Act, 2013. There are no cases filed / complaints lodged in the Company during the year under review in respect of the Sexual Harassment of Women at workplace.



Phyto Chem (India) Limited

13. Disclosures:

Pecuniary disclosure with regard to interested Directors:

- a. Disclosures on materially significant related party transactions of the Company of material nature, with its Promoters, the Directors or the Management, their Subsidiaries or Relatives, that may have potential conflict with the interests of the Company at large:-**

None of the transactions with any of related parties was in conflict with interest of the Company.

- b. Details of non-compliance by the Company and the penalties, strictures imposed on the Company by Stock Exchange or SEBI or any Statutory Authority, on any matter related to Capital Markets during the last three years:-**

There were no instances of non-compliance of any matter related to Capital Market during the last three years and no penalties or fines imposed by any Statutory Authorities.

- c. Compliance Certificate of the Auditors:**

Certificate of the Statutory Auditor's has been obtained on the compliance of the conditions of Corporate Governance in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with Stock Exchanges and the same is annexed.

- d. Details of compliance with mandatory requirements and adoption of the non-mandatory requirements of this clause:**

The Company has fully complied with the mandatory requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 of the Stock Exchange.

- e. The Management Discussion and Analysis is a part of this Annual Report.**

- f. Certificate from Company Secretary in Practice:**

M/s. Puttaparthi Jagannatham & Co., Practicing Company Secretaries, have issued a certificate as required under the Listing Regulations, confirming that none of the Directors on the Board of the Company has been debarred or disqualified from being appointed or continuing as Director of Companies by the SEBI/ Ministry of Corporate Affairs or any such statutory authority. The certificate is enclosed with this section as Annexure - A.

14. Means of Communication:

- a. The Company publishes its quarterly, half yearly and annual results in the Business Standard and Andhra Prabha (Telugu). These results are submitted to the Stock Exchange in accordance with the permission of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- b. Website : www.phytochemindia.com
- c. E-mail Id : investorsrelations@phytochemindia.com

15. General information for members:

- a. Thirty Second Annual General Meeting:**

Date, Time & Venue: Monday, the 27th day of September 2021 at 11:45 A.M.
M/s Phyto Chem (India) Limited, Regd. Office: Survey No.628,
Temple Street, Bonthapally - 502 313, Gummadidala Mandal,
Sangareddy District, Telangana State.

- b. Financial Calendar:**

Results	For 2020-21 were announced on	For 2021-22 will be announced by
First Quarter	14 th September 2020	14 th August 2021
Second Quarter/ Half Year	12 th November 2020	14 th November 2021
Third Quarter	12 th February 2021	14 th February 2022
Yearly- Audited Results	30 th June 2021	30 th May 2022

Phyto Chem - Annual Report - 2020-21

c. Dates of Book Closure:

21st September 2021 to 27th September 2021 both days inclusive.

d. Dividend Payment Date: Not Applicable

e. i. Stock Exchanges where listed:

Bombay Stock Exchange Limited, P.J. Towers, Dalal Street,
Mumbai - 400 001.

ii. Stock Code (BSE): 524808

f. Market Price Data:

The market price data High/Low during each month in the last financial year (2020-21) at the Bombay Stock Exchange Limited, Mumbai is as follows:-

Period	Bombay Stock Exchange Limited		
	High-in Rs.	Low-in Rs.	Volume - No.of Shares
April 2020	25.05	18.10	7,174
May 2020	27.80	23.85	484
June 2020	30.00	24.20	2,342
July 2020	28.20	21.10	3,988
August 2020	27.85	22.15	7,934
September 2020	25.85	20.80	4,582
October 2020	26.95	19.40	10,012
November 2020	26.40	20.45	24,638
December 2020	27.25	20.30	1,23,502
January 2021	32.60	24.05	80,612
February 2021	26.90	19.95	65,767
March 2021	22.20	16.05	94,964

g. Share Transfer Agent:

M/s. Bigshare Services Private Limited, 306, 3rd Floor, Right Wing, Amrutha Ville, Opp : Yashoda Hospital, Somajiguda, Rajbhavan Road, Hyderabad - 500 082, Ph.No. 040-23374967.

h. Distribution of Shareholding by ownership as on 31-03-2021:

Sl. No.	Shareholding Pattern	Shares	Shareholding %
1	Promoters	1737393	40.40
2	Indian Public	2224162	51.72
3	Mutual Funds	8000	0.19
4	Body Corporates	234839	5.46
5	NRI- Non Promoters	78116	1.82
6	Clearing Members	17690	0.41
	Total:	4300200	100.00

i. Distribution of Shareholding by size as on 31-03-2021:

Range of Shares	No.of Shareholders	No.of Shares	% of Shareholders	% of Holding
Upto 500	6491	8697480	91.68	20.23
501-1000	272	2279020	3.84	5.30
1001-2000	135	2086510	1.91	4.85
2001-3000	48	1184770	0.68	2.76
3001-4000	25	900060	0.35	2.09
4001-5000	15	690370	0.21	1.61
5001-10000	41	2833590	0.58	6.59
10001 and above	53	24330200	0.75	56.58
Total	7080	43002000	100.00	100.00



Phyto Chem (India) Limited

j. Your Company has not issued any GDRs/ADRs/Warrants or any convertible instruments or ESOPS.

k. **Plant Location:**

Survey No.628, Temple Street, Bonthapally - 502 313. Gummadidala Mandal, Sangareddy District, Telangana State.

l. **Compliance with the Regulation 39(4) read with Schedule VI of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015:**

There are no shares issued pursuant to Public Issue or any other issue which remain unclaimed.

m. **Address for Correspondence :**

Shareholders Correspondence may be made with the Company's Share Transfer Agents at the address given at (g) above. In case of any difficulty, shareholders may contact Mr. Pavansingh Thakur, Compliance Officer at the Corporate Office at No.8-3-229/23, First Floor, Thaherville, Yousufguda Checkpost, Hyderabad - 500 045, Telangana, at e-mail : compliances@phytochemindia.com.

The Report has not covered the non-mandatory requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Declaration by M.D. (CEO) of the Company on Code of Conduct

DECLARATION

As provided under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with the Stock Exchange, the Board Members, Key Managerial Personnel and the Senior Management Personnel have confirmed compliance with the Code of Conduct for the year ended 31st March 2021.

**Place : Hyderabad
Date : 14th August 2021**

**(Y.Nayudamma)
Managing Director & CEO
DIN: 00377721**

Phyto Chem - Annual Report - 2020-21

Chief Executive Officer (CEO) and Chief Financial Officer (CFO) Certification

To

The Board of Directors

M/s Phyto Chem (India) Limited,
Survey No. 628, Temple Street,
Bonthapally - 502 313,
Gummadidala Mandal, Sangareddy District,
Telangana State.

We certify that :

We have reviewed the financial statements and the cash flow statement of M/s Phyto Chem (India) Limited for the year ended March 31, 2021 and that to the best of our knowledge and belief:

- a. i. These statements do not contain any materially untrue statement or omit any material fact or contain statements that may be misleading;
- ii. These statements together present a true and fair view of the Company's affairs and are in compliance with current accounting standards, applicable laws and regulations.
- b. There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or in violation of the Company's code of conduct.
- c. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company and have disclosed to the Auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, and the steps taken or proposed to be taken to rectify these deficiencies.
- d. We have indicated to the Auditors and the Audit committee:
 - i. Significant changes, if any, in internal control over financial reporting during the year;
 - ii. Significant changes, if any, in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - iii. That there were no instances of significant fraud of which we have become aware and involvement therein, if any of management or other employees having a significant role in the Company's internal control system over financial reporting.

Place : Hyderabad,
Date : 14th August 2021

Y. Nayudamma
Chief Executive Officer
DIN: 00377721

B. Sambasiva Rao
Chief Financial Officer



Phyto Chem (India) Limited

Auditor's Report on Corporate Governance

To
The Members of Phyto Chem (India) Limited

We have examined the relevant records relating to compliance of conditions of Corporate Governance by Phyto Chem (India) Limited ("the Company"), for the year ended 31st March 2021, as per the relevant provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') as referred to in Regulation 15(2) of the Listing Regulations for the year ended 31st March 2021.

The compliance of conditions of Corporate Governance is the responsibility of the Management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring compliance with the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in above mentioned Listing Regulations.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Puttaparthi Jagannatham & Co.

Navajyoth Puttaparthi
Practicing Company Secretary
COP No: 16041: M. NO: F9896
UDIN: F009896C000775089

Place : Hyderabad
Date : 12th August 2021

Phyto Chem - Annual Report - 2020-21

Annexure A

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
The Members of
Phyto Chem (India) Limited
Survey No. 628, Temple Street, Bonthapally - 502313
Gummadidala Mandal, Sangareddy District
Telangana, India

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Phyto Chem (India) Limited having CIN L24110TG1989PLC009500 and having registered office at Survey No. 628, Temple Street, Bonthapally - 502313, Gummadidala Mandal, Sangareddy District, Telangana, India (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers, We hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March 2021 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

Sr. No.	Name of Director	DIN	Date of appointment in Company
1	Dr. Venkateswarlu Yadlapalli	00377568	16-03-1994
	a. Mr. Srinivasa Rao Koduri	03334048	11-02-2017
2	Dr. Sreemannarayana Prathipati	00377472	05-12-1994
3	Mr. Anjaneyulu Prathipati	00377635	21-07-2002
4	Mr. Nayudamma Yarlagadda	00377721	01-06-2009
5	Mr. Janaki Ramaiah Yarlagadda	06949910	29-07-2014
6	Dr. Seeta Ram Anjaneyulu Gorantla	01874325	26-08-2017
7	Mr. Sree Ram Murthy Mandava	01932910	14-08-2019
8	Mr. Ravindra Babu Kakarla	00328421	12-11-2020
9	Mr. Yugandhar Sampath Kumar Sakhamuri	02389255	12-11-2020
10	Mrs. Vijitha Gorrepati	03492979	12-11-2020

Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

**For Puttaparthi Jagannatham & Co.,
Company Secretaries**

**CS Navajyoth Puttaparthi
Partner,**

**Place : Hyderabad
Date : 12th August 2021**

**FCS No: 9896 ; C P No.: 16041
UDIN: F009896C000775012**



Phyto Chem (India) Limited

Independent Auditor's Report

To

The Members of Phyto Chem (India) Limited

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of Phyto Chem (India) Limited ('the Company'), which comprise the Balance Sheet as at March 31, 2021, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year ended on that date, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as 'the financial statements').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 as amended ('Ind AS') and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021, the profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

Sl. No.	Key Audit Matter	Auditor's Response
1	<p>Accuracy of recognition, measurement, presentation and disclosures of revenues and other related balances in view of adoption of Ind AS 115 'Revenue from Contracts with Customers' (new Indian Accounting Standard on revenue)</p> <p>The application of the new revenue accounting standard involves certain key judgements relating to identification of distinct performance obligations, determination of transaction price of the identified performance obligations, the</p>	<p>Auditor's Response Principal Audit Procedures We assessed the Company's process to identify the impact of adoption of the new revenue accounting standard. Our audit approach consisted testing of the design and operating effectiveness of the internal controls and substantive testing as follows :</p> <p>Evaluated the design of internal controls relating to implementation of the new revenue accounting standard. Selected a sample of continuing and new contracts, and tested the operating effectiveness of the internal control, relating to identification of the distinct</p>

Phyto Chem - Annual Report - 2020-21

Sl. No.	Key Audit Matter	Auditor's Response
	<p>appropriateness of the basis used to measure revenue recognized over a period. Additionally, new revenue accounting standard contains disclosures which involves collation of information in respect of disaggregated revenue and periods over which the remaining performance obligations will be satisfied subsequent to the balance sheet date. Refer to Notes 2.11 to the Financial Statements</p>	<p>performance obligations and determination of transaction price. We carried out a combination of procedures involving enquiry and observation, re-performance and inspection of evidence in respect of operation of these controls.</p> <p>Tested the relevant information technology systems' access and change management controls relating to contracts and related information used in recording and disclosing revenue in accordance with the new revenue accounting standard.</p> <p>Selected a sample of continuing and new contracts and performed the following procedures:</p> <ul style="list-style-type: none"> - Read, analysed and identified the distinct performance obligations in these contracts. - Compared these performance obligations with that identified and recorded by the Company. - Considered the terms of the contracts to determine the transaction price including any variable consideration to verify the transaction price used to compute revenue and to test the basis of estimation of the variable consideration. - Samples in respect of revenue recorded for time and material contracts were tested using a combination of approved time sheets including customer acceptances, subsequent invoicing and historical trend of collections and disputes. - Sample of revenues disaggregated by type and service offerings was tested with the performance obligations specified in the underlying contracts. - In respect of samples relating to fixed-price contracts, progress towards satisfaction of performance obligation used to compute recorded revenue was verified with actual and estimated efforts from the time recording and budgeting systems. We also tested the access and change management controls relating to these systems. - Sample of revenues disaggregated by type and service offerings was tested with the performance obligations specified in the underlying contracts. - Performed analytical procedures for reasonableness of revenues disclosed by type and service offerings. - We reviewed the collation of information and the logic of the report generated from the budgeting system used to prepare the disclosure relating to the periods over which the remaining performance obligations will be satisfied subsequent to the balance sheet date.



Phyto Chem (India) Limited

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- * Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- * Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.

Phyto Chem - Annual Report - 2020-21

- * Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- * Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- * Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ('the Order') issued by the Central Government in terms of Section 143 (11) of the Act, we give in Annexure-A a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by Section 143(3) of the Act, based on our audit we report that :
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) the Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.
 - d) In our opinion, the aforesaid financial statements comply with the Ind AS specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e) On the basis of the written representations received from the directors as on March 31, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in 'Annexure-B'. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial



Phyto Chem (India) Limited

3. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us :
- i. The Company has disclosed the impact of pending litigations on its financial position in its financial
 - ii. The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts.
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the company.
 - iv. The disclosures in the financial statements regarding holdings as well as dealings in specified bank notes during the period from 8 November 2016 to 30 December 2016 have not been made in these financial statements since they do not pertain to the financial year ended 31st March 2021.

4. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of amendments to section 197(16) of the Act:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act.

**For M/s S.T.Mohite & Co.,
Chartered Accountants
Firm Regn. No. 011410S**

**Place : Hyderabad
Date : 30th June 2021**

**Sreenivasa Rao. T. Mohite
Partner, M.No.015635,
ICAI:UDIN:21015635AAAADH6685**

Phyto Chem - Annual Report - 2020-21

Annexure A to the Independent Auditors' Report

With reference to Annexure A as referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report to the Members of the company on the standalone financial statement for the year ended 31st March 2021, we report the following:

Sl No.	Ref to CARO	Report by Independent Auditors
1	3(i)	Fixed Assets
	3(i)(a)	The Company has maintained proper records showing full particulars including quantitative details and situation of fixed assets on the basis of available information.
	3(i)(b)	The Company has a regular program of physical verification of its fixed assets, by which all fixed assets are verified on annual basis, in our opinion, the periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, all fixed assets were physically verified during the year. According to the information and explanation given to us, no material discrepancies were noticed on such verification.
	3(i)(c)	According to the information and explanations given to us and the records examined by us and based on the examination of sale deeds, conveyance deeds, encumbrance certificates verified by us, we report that the title deeds comprising all the immovable properties of lands, buildings which are free hold, are in the name of the Company as at the Balance sheet date.,
2	3(ii)	Inventories
		As explained to us, the inventories has been physically verified by the management during the year. In our opinion, the frequency of such verification is reasonable. The Company has maintained proper records of inventory. There were no material discrepancies noticed on verification between the physical stock and the book records.
3	3(iii)	Loans to parties covered by Sec.189 of the Companies Act,2013 ('the Act')
		According to the information and explanation given to us, the Company has not granted any loans, secured or unsecured to Body corporate, Firms, Limited Liability Firms or other parties covered in the register required to be maintained under section 189 of the Act for loans, guarantees, securities. Accordingly the provisions of the clause 3 (iii) of the Order are not applicable to the Company for the year under review.
4	3(iv)	Loans, guarantees, securities to and investments in other companies
		In our opinion and according to the information and explanation given to us, the company has no transactions for compliance with the provisions of Sections 185 and 186 and complied with the provisions of Section 186 of the Act in respect of investments made and loans given.
5	3(v)	Acceptance of deposits
		In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits during the year as per provisions of Section 73 or 76 of the Act or any other relevant provisions of the Act and the relevant Rules framed thereunder. Accordingly the provisions of the Para 3 (v) of the Order are not applicable to the Company for the year under review.
6	3(vi)	Maintenance of cost records
		According to the information and explanations given us, the maintenance of cost records prescribed by the Central Government under section 148(1) of the Act read with Rule 3 of the Cost Audit Rules is not applicable to the company. Accordingly cost audit under Sec.148(2) of the Act read with Rule 4 of the Cost Audit Rules is not applicable to the Company for the year under review. Accordingly Para 3(vi) of the Order is not applicable for the Company.



Phyto Chem (India) Limited

7	3(vii)	Statutory Dues
	3(vii)(a)	According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted / accrued in the books of account in respect of undisputed statutory dues including Provident Fund, Employee's State Insurance, Income Tax, Goods and Service Tax, duty of Customs, Cess and other material statutory dues have been generally deposited during the year by the Company with the appropriate authorities. According to the information and explanations given to us, no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income tax, Goods and Service Tax, duty of Customs, Cess and other material statutory dues in arrears as at March 31, 2021 for a period of more than six months from the date they became payable.
	3(vii)(b)	According to the information and explanation given to us, there are no dues of statutory dues of Income tax, sales tax, Service tax, Goods and Service tax, Customs duty, Excise duty, Value added tax, cess and other dues that have not been deposited by the Company on account of any disputes.
8	3(viii)	Defaults in repayments to Financial Institutions/Banks/Debenture holders
		In our opinion and according to the information and explanation given to us, the Company has not defaulted in the payment/repayments of loans or borrowings to the banks.
9	3(ix)	Initial public offer/further offer
		In our opinion and according to the information and explanation given to us, the company has not made, during the year under review, any initial public offer or further public offer of securities (including debt instruments). The term loans raised during the year are applied for the purpose for which they are drawn.
10	3(x)	Frauds by or on the Company
		In our opinion and according to the information and explanation given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the course of our audit.
11	3(xi)	Managerial Remuneration
		In our opinion and according to the information and explanation given to us based on the examination of the records of the Company, the Company has paid/provided managerial remuneration in accordance with the requisite approvals and compliances mandated by the provisions of section 197 read with Schedule V to the Act.
12	3(xii)	Nidhi company
		In our opinion and according to the information and explanation given to us, the Company is not a Nidhi Company as prescribed under Section 406 of the Act and hence paragraph 3(xii) of the Order is not applicable to the Company.
13	3(xiii)	Transactions with Related parties
		In our opinion and according to the information and explanation given to us and based on our examination of the records of the Company, all transactions with related parties are in compliance with provisions of section 177 and section 188 of the Act where applicable, and the details of such transactions have been disclosed in the standalone financial statements as required by the applicable Indian Accounting Standards.
14	3(xiv)	Preferential allotment u/s 62 or private placement u/s 42 of the Act
		In our opinion and according to the information and explanation given to us and based on our examination of the records, the Company has not made any preferential allotment of equity shares during the year. There is no private placement of shares by the Company under section 42 of the Act during the year. Accordingly Paragraph 3(xiv) of the Order is not applicable to the Company for the period under review.

Phyto Chem - Annual Report - 2020-21

15	3(xv)	Non-cash transactions with directors u/s 192 of the Act
		In our opinion and according to the information and explanation given to us and based on our examination of the records of the Company, the Company has not entered during the year into any non-cash transactions with its Directors or persons connected to its Directors and hence provisions of Sec 192 of the Act and paragraph 3(xv) of the Order are not applicable to the Company.
16	3(xvi)	Registration u/s 45-1A of Reserve Bank of India Act,1934
		According to the information and explanation given to us, the Company is not required to be registered under section 45-1A of the Reserve bank of India Act, 1934 and hence paragraph 3(xvi) of the Order is not applicable to the Company.

Place : Hyderabad
Date : 30th June 2021

**For M/s S.T.Mohite & Co.,
Chartered Accountants
Firm Regn. No. 011410S**

**Sreenivasa Rao. T. Mohite
Partner, M.No.015635,
ICAI:UDIN:21015635AAAADH6685**



Phyto Chem (India) Limited

Annexure-B to the Independent Auditor's Report

(Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' section of our report to the Members of Phyto Chem (India) Limited of even date)

Report on the Internal Financial Controls Over Financial Reporting under Para (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

We have audited the internal financial controls over financial reporting of Phyto Chem (India) Limited ("the Company") as of March 31, 2021 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Board of Directors of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to respective Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company.

Meaning of Internal Financial Controls over Financial Reporting

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the

Phyto Chem - Annual Report - 2020-21

company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Place : Hyderabad
Date : 30th June 2021

**For M/s S.T.Mohite & Co.,
Chartered Accountants
Firm Regn. No. 011410S**

**Sreenivasa Rao. T. Mohite
Partner, M.No.015635,
ICAI:UDIN:21015635AAAADH6685**



Phyto Chem (India) Limited

Balance sheet as at 31st March 2021

(All amounts in Indian Rupees, except otherwise stated)

Particulars	Note No.	As at 31 st March 2021	As at 31 st March 2020
ASSETS			
Non-current assets			
(a) Property, Plant and Equipment	3	34,343,587	46,729,996
(b) Capital work-in-progress		-	-
(c) Investment properties		-	-
(d) Intangible assets		-	-
(e) Financial assets			
(i) Investments	4	1,582,928	1,119,818
(ii) Loans	5	1,938,965	2,723,965
(iii) Other financial assets	6	4,110,109	4,447,510
(f) Deferred tax assets (Net)		-	-
(g) Other non-current assets		-	-
Total Non-current assets		41,975,589	55,021,289
Current assets			
(a) Inventories	7	161,224,463	168,337,063
(b) Financial assets			
(i) Trade receivables	8	222,889,801	436,522,239
(ii) Cash and cash equivalents	9	616,069	493,490
(iii) Bank Balances other than Cash and cash equivalents	10	643,888	1,310,561
(iv) Loans and advances		-	-
(v) Other financial assets		-	-
(c) Current tax assets (Net)		-	-
(d) Other current assets	11	23,942,043	14,215,413
Total Current assets		409,316,264	620,878,766
TOTAL ASSETS		451,291,853	675,900,055
EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital	12	43,002,000	43,002,000
(b) Other equity	13	58,843,203	55,475,904
Total Equity		101,845,203	98,477,904
Liabilities			
Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	14	36,258,938	31,273,263
(ii) Other financial liabilities	15	12,219,445	12,429,489
(b) Provisions			
(c) Deferred tax liabilities (Net)	16	(3,304,573)	(1,068,463)
Total Non-current liabilities		45,173,810	42,634,289
Current liabilities			
(a) Financial liabilities			
(i) Borrowings	14	156,443,792	189,632,698
(ii) Trade Payables	17	-	-
A. Total outstanding dues of Micro, Small & Medium Enterprises		-	-
B. Total outstanding dues other than Micro, Small & Medium Enterprises		103,101,862	311,308,036
(iii) Other financial liabilities	18	21,600,108	10,173,143
(b) Other current liabilities	19	12,089,051	14,173,7201
(c) Provisions	20	9,138,027	8,150,265
(d) Current tax liability (Net)	21	1,900,000	1,350,000
Total current liabilities		304,272,840	534,787,862
TOTAL LIABILITIES		349,446,650	577,422,151
TOTAL EQUITY AND LIABILITIES		451,291,853	675,900,055
See accompanying notes forming part of financial statements			
General Information	1		
Summary of significant accounting policies	2		
Notes to Financial Statements	29-50		

As per our Report of even date attached

For M/s S.T. Mohite & Co.,
Chartered Accountants
Firm Regn. No. 011410S

Sreenivasa Rao. T. Mohite
Partner, M.No.015635
UDIN:21015635AAAADH6685
Place : Hyderabad
Date : 30th June 2021

For and on behalf of the Board of Directors

Y. Nayudamma
Managing Director
DIN : 00377721

Pavansingh Thakur
Company Secretary
M.No: 56920

Place : Hyderabad
Date : 30th June 2021

G.S.R.Ananeylu
Director
DIN : 01874325

B. Sambasiva Rao
Chief Financial Officer

Phyto Chem - Annual Report - 2020-21

Statement of Profit and Loss for the year ended 31st March 2021

(All amounts in Indian Rupees, except otherwise stated)

Particulars	Note No.	Year ended 31 st March 2021	Year ended 31 st March 2020
I Revenue from operations	22	444,880,323	442,227,889
II Other income	23	8,046,841	13,825,669
III Total revenue (I+II)		<u>452,927,164</u>	<u>456,053,558</u>
IV Expenses			
Cost of materials consumed	24	368,653,594	345,490,640
Changes in inventories of finished goods, land & work in progress	25	(15,339,735)	6,684,432
Employee benefit expense	26	32,092,482	35,500,234
Finance cost	27	21,167,809	24,693,956
Depreciation and amortisation expense	3	4,258,363	4,096,016
Other expense	28	37,429,565	35,362,034
Total expenses (IV)		<u>448,262,078</u>	<u>451,827,312</u>
V Profit before exceptional items and tax (III - IV)		<u>4,665,086</u>	<u>4,226,246</u>
VI Exceptional items		-	-
VII Profit/(loss) before tax (V-VI)		<u>4,665,086</u>	<u>4,226,246</u>
VIII Tax expense			
Current tax		1,900,000	1,350,000
Deferred tax		(2,165,456)	(1,581,107)
Earlier year tax adjustments		-	-
Total Tax expense (VIII)		<u>(265,456)</u>	<u>(231,107)</u>
IX Profit/(loss) for the period After Tax (VII - VIII)		<u>4,930,542</u>	<u>4,457,352</u>
X Other comprehensive income			
Items not to be reclassified to profit or loss in subsequent periods:			
Re-measurement of defined employee benefit plans		73,934	(204,582)
Fair valuation of Investments		463,110	(108,625)
Deferred tax relating to item (a&b) above		(122,983)	71,724
Items to be reclassified to profit or loss in subsequent periods:			
Re-measurement of defined employee benefit plans		-	-
Change in Fair Value of FVOCI Financial Liabilities		67,871	29,814
Deferred tax relating to item (a&b) above		15,542	6,827
Other comprehensive income/(loss) for the year		<u>497,474</u>	<u>(204,842)</u>
XI Total Comprehensive Income for the period (IX+X)		<u>5,428,016</u>	<u>4,252,511</u>
XII Earnings per equity share			
a) Basic		1.15	1.04
b) Diluted		1.15	1.04
See accompanying notes forming part of financial statements			
General Information	1		
Summary of significant accounting policies	2		
Notes to Financial Statements	29-50		

As per our Report of even date attached

**For M/s S.T. Mohite & Co.,
Chartered Accountants
Firm Regn. No. 011410S**

**Sreenivasa Rao. T. Mohite
Partner, M.No.015635
UDIN:21015635AAAADH6685
Place : Hyderabad
Date : 30th June 2021**

For and on behalf of the Board of Directors

**Y. Nayudamma
Managing Director
DIN : 00377721**

**Pavansingh Thakur
Company Secretary
M.No: 56920**

**Place : Hyderabad
Date : 30th June 2021**

**G.S.R.Anjaneyulu
Director
DIN : 01874325**

**B. Sambasiva Rao
Chief Financial Officer**



Phyto Chem (India) Limited

Cash flow statement for the year ended March 31, 2021

(All amounts in Indian Rupees, except otherwise stated)

Particulars	Year Ended 31 st March 2021	Year Ended 31 st March 2020
A. Cash flows from Operating activity:		
Net Profit Before tax and extra-ordinary items:	4,665,086	4,226,246
Add: Non Cash expenditure:		
Depreciation expense	4,258,363	4,096,016
Less: Non cash incomes		
Less: Income from financing or investing activities:		
Dividend income	(1,533,500)	(130,500)
Profit on sale of fixed assets	(3,413,372)	(12,397)
Add: Expenditures of financing or investing activities:		
Interest expenses	21,167,809	24,693,956
Operating profit before working capital changes	25,144,386	32,873,322
Adjustments for Changes in working capital		
Add: Increase in current liabilities	-	-
Add: Decrease in current assets	208,155,508	53,836,235
Less: Decrease in current liabilities	(241,180,800)	(71,657,504)
Less: Increase in current assets	-	(191,268)
Cash generated from operating activities	(7,880,906)	14,860,785
Less: Income tax paid	265,456	231,107
Cash flow before extraordinary items	(7,615,450)	15,091,892
Add/(Less): Extraordinary items	-	-
Other Comprehensive Income	497,474	(204,842)
Net cash flow from operating activities (A)	(7,117,976)	14,887,050
B. Cash flows from Investing activities		
Purchase of fixed assets	(1,869,920)	(4,571,769)
Proceeds from sale of fixed assets	9,997,965	63,455
Income received on chit contributions	1,533,500	130,500
Profit on sale of fixed assets	3,413,372	-
Proceeds from sale of securities	(463,110)	108,625
Repayment of advances or loans from third parties etc.	-	338,417
Increase in gratuity fund	(2,060,706)	-
Net cash flow from Investing activities (B)	10,551,101	(3,930,772)
C. Cash flows from Financing activities		
Proceeds from the issue of share capital	-	-
Proceeds from long-term borrowings	16,068,188	13,387,758
Repayment of long term borrowings	1,122,402	-
Other long term liabilities	-	278,049
Interest paid	(21,167,809)	(24,693,956)
Net cash flow from Financing activities (C)	(3,977,219)	(11,028,149)
Net Increase/Decrease in Cash and cash equivalents	(544,094)	(71,872)
Add: Opening Cash and cash equivalents	1,804,050	1,875,925
Closing Cash and cash equivalents	1,259,956	1,804,050

Note: The Cash Flow Statement has been prepared under the Indirect Method as set out in the Ind AS-7 on - "Statement of Cash Flow "

CERTIFICATE

The above Cash flow statement has been prepared on the basis of Audited Accounts approved by the Board of Directors and is in agreement with the Statement of Profit and Loss and Balance sheet as at 31st March 2021.

As per our Report of even date attached

For M/s S.T. Mohite & Co.,
Chartered Accountants
Firm Regn. No. 011410S

Sreenivasa Rao. T. Mohite
Partner, M.No.015635
UDIN:21015635AAAADH6685
Place : Hyderabad
Date : 30th June 2021

For and on behalf of the Board of Directors

Y.Nayudamma
Managing Director
DIN : 00377721

G.S.R.Anjaneyulu
Director
DIN : 01874325

Pavansingh Thakur
Company Secretary
M.No: 56920

B. Sambasiva Rao
Chief Financial Officer

Place : Hyderabad
Date : 30th June 2021

Phyto Chem - Annual Report - 2020-21

Statement of changes in equity for the year ended 31st March 2021

(All amounts in Indian Rupees, except otherwise stated)

a. Equity share capital

(Rs. In Lakhs)

Balance at the end of the reporting period i.e. 31 st March 2020	Changes in equity share capital during the year	Balance at the end of the reporting period i.e. 31 st March 2021
43,002,000	-	43,002,000

b. Other equity - Reserves & surplus / Other comprehensive income

Particulars	Capital Reserve	Securities Premium Reserve	General Reserve	Retained Earnings	Equity Instruments Through OCI	Remeasurement of Defined Benefit Plan	Debt Instruments through OCI	Total
As on 31st March 2020								
Balance at the beginning of the reporting period i.e., 1 st April 2019	-	-	36,010,837	15,735,351	(522,795)	-	-	51,223,393
Profit for the Year	-	-	-	4,457,352	-	-	-	4,457,352
Total Comprehensive Income for the year	-	-	-	(313,467)	108,625	-	-	(204,842)
Transfer to/(from) Retained Earnings	-	-	-	-	-	-	-	-
Dividend Paid on Equity Shares	-	-	-	-	-	-	-	-
Tax on Dividend Paid on Equity Shares	-	-	-	-	-	-	-	-
Balance at the end of the reporting period i.e. 31st March 2020	-	-	36,010,837	19,879,237	(414,170)	-	-	55,475,904
As on 31st March 2021								
Balance at the beginning of the reporting period i.e., 1 st April 2020	-	-	36,010,837	19,879,237	(414,170)	-	-	55,475,904
Profit for the Year	-	-	-	4,930,542	-	-	-	4,930,542
Total Comprehensive Income for the year	-	-	-	960,585	(463,110)	-	-	497,475
Transfer to/(from) Retained Earnings	-	-	-	(2,060,718)	-	-	-	(2,060,718)
Dividend Paid on Equity Shares	-	-	-	-	-	-	-	-
Tax on Dividend Paid on Equity Shares	-	-	-	-	-	-	-	-
Balance at the end of the reporting period i.e. 31st March 2021	-	-	36,010,837	23,709,646	(877,280)	-	-	58,843,203

As per our Report of even date attached

For M/s S.T. Mohite & Co.,
Chartered Accountants
Firm Regn. No. 011410S

Sreenivasa Rao, T. Mohite
Partner, M.No.015635
UDIN:21015635AAAADH6685
Place : Hyderabad
Date : 30th June 2021

For and on behalf of the Board of Directors

Y. Nayudamma
Managing Director
DIN : 00377721

Pavansingh Thakur
Company Secretary
M.No: 56920

Place : Hyderabad
Date : 30th June 2021

N. Sudhakar
Director
DIN : 00426897

B. Sambasiva Rao
Chief Financial Officer



Phyto Chem (India) Limited

Notes to financial statements for the year ended 31st March 2021

(All amounts in Lakhs, except otherwise stated)

Note 1: General information:

Phyto Chem (India) Limited was incorporated on 11th January 1989 having its registered office at Bonthapally, Telangana State, India. It is incorporated under the Companies Act as limited company and is limited by shares. The shares of the Company are listed on the Bombay Stock Exchange Limited, Mumbai. The company is engaged in manufacturing of Pesticides. The financial statements were approved for issue by the Board of Directors on 30th June 2021.

The principal accounting policies applied in the preparation of the financial statements are set out below:

Note 2: Basis of Preparation and Presentation of Financial Statements:

The financial statements of Phyto Chem (India) Limited ("the Company") for the year ended 31st March 2021 have been prepared and presented in accordance with the Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

The financial statements have been prepared on historical cost convention on accrual basis of accounting except for certain financial instruments that are measured at fair value. GAAPs of Indian Accounting Standards as specified in Section 133 of the Act read together with Rule 4 of Companies (Indian Accounting Standard) Amendment Rules, 2016 to the extent applicable, pronouncements of regulatory bodies applicable to the Company and other provisions of the Act. Accounting Policies have been consistently applied except where a newly issued Accounting Standards is initially adopted or revision to existing Accounting Standards requires a change in the accounting policy hitherto in use. Management evaluates all recently issued or revised Accounting Standards on an on-going basis.

2.1 Basis of Measurement:

All assets and liabilities are classified into current and non-current based on the operating cycle of twelve months or based on the criteria of realisation/ settlement within twelve months period from the reporting/ Balance sheet date.

Assets: An asset is classified as current when it satisfies any of the following criteria:

- It is expected to be realized in, or is intended for sale or consumption in, the Company's normal operating cycle;
- It is held primarily for the purpose of being traded;
- It is expected to be realized within twelve months after the reporting date; or
- It is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date.

Liabilities: A liability is classified as current when it satisfies any of the following criteria:

- It is expected to be settled in the Company's normal operating cycle;
- It is held primarily for the purpose of being traded;
- It is due to be settled within twelve months after the reporting date; or
- The Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

Current assets/ liabilities include the current portion of noncurrent assets/ liabilities respectively. All other assets/ liabilities are classified as noncurrent. Deferred tax assets and liabilities are always disclosed as non-current.

2.2 Operating Cycle:

Operating cycle is the time between the acquisition of assets for processing and their in cash and cash equivalents. The company has ascertained its operating cycle as twelve months for the purpose of current/non-current classification of assets and liabilities.

Phyto Chem - Annual Report - 2020-21

2.3 Accounting Estimates:

The preparation of the financial statements, in conformity with the recognition and measurement principles of Ind AS, requires the management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as at the date of financial statements and the results of operation during the reported period. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates which are recognized in the period in which they are determined.

- a. **Depreciation and amortization:** Depreciation and amortization is based on Schedule II to the Companies Act, 2013, which describes useful lives of property, plant and equipment and intangible assets.
- b. **Provisions and contingencies:** Provisions and contingencies are based on the Management's best estimate of the liabilities based on the facts known at the balance sheet date.
- c. **Fair valuation:** Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows: Level 1: Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date; Level 2: Inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and Level 3: Inputs are unobservable inputs for the asset or liability. For assets and liabilities that are recognized in the Financial Statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period. At each reporting date, the Company analyses the movements in the values of assets and liabilities which are required to be re-measured or reassessed in line with the Company's Accounting Policies. For this analysis, the Company verifies the major inputs applied in the latest valuation by agreeing the information in the valuation computation to contracts and other relevant documents. For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

2.4 Critical Accounting Judgements and Key source of estimation uncertainty operating cycle:

In the application of the Company's accounting policies, the management of the Company are required to make judgments, estimates, and assumptions about the carrying amounts of the assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to the accounting estimates are recognized in the period in which the estimates is revised if the revision effects only that period or in the period of the revision and future periods in the revision effects both current and future periods. The following are the areas of estimation uncertainty and critical judgements that the management has made in the process of applying the Company's accounting policies and that have the most significant effects on the amounts recognized in the financial statements.

2.5 Provisions and contingent liability:

On an ongoing basis, Company reviews pending cases, claims by third parties and other. For contingent losses that are considered probable an estimated loss is recorded as an accrual in financial statements. Loss Contingencies that are considered possible or not provided for but disclosed as Contingent liabilities in the financial statements. Contingencies the likelihood of which is remote are not disclosed in the financial statements. Gain contingencies are not recognized until the contingency has been resolved and amounts are received or receivable.



Phyto Chem (India) Limited

2.6 Useful lives of depreciable assets:

Management reviews the useful lives of depreciable assets at each reporting. As at March 31, 2021 management assessed that the useful lives represent the expected utility of the assets to the company. Further, there is no significant change in the useful lives as compared to previous year.

2.7 Functional and presentation currency:

These financial statements are presented in Indian rupees, which is also the functional currency of the Company. All financial information presented in Indian rupees.

Foreign Currencies :

In preparing the financial statements of the Company transactions in currencies other than the entity's functional currency (foreign currencies) are recognised at the rates of exchange prevailing at the dates of transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-Monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing at the date when fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

For the purpose of presenting these financial statements, the assets and liabilities of the company's foreign operations are translated into currency units using exchange rates prevailing at the end of each reporting period.

2.8 Property Plant & Equipment:

Recognition and measurement:

Property, Plant and Equipment are stated at cost of acquisition or construction less accumulated depreciation and impairment loss, if any. Cost includes expenditures that are directly attributable to the acquisition of the asset i.e., freight, duties and taxes applicable and other expenses related to acquisition and installation. The cost of self-constructed assets includes the cost of materials and other costs directly attributable to bringing the asset to a working condition for its intended use. Borrowing costs that are directly attributable to the construction or production of a qualifying asset are capitalized as part of the cost of that asset. When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

Gains and losses upon disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognized net within in the statement of profit and loss.

The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The costs of repairs and maintenance are recognized in the statement of profit and loss as incurred.

Items of property, plant and equipment acquired through exchange of non-monetary assets are measured at fair value, unless the exchange transaction lacks commercial substance or the fair value of either the asset received or asset given up is not reliably measurable, in which case the asset exchanged is recorded at the carrying amount of the asset given up. Property, Plant and Equipment which are not ready for intended use as on the date of balance sheet are disclosed as "Capital Work-in-Progress".

Depreciation:

Depreciation is recognized in the statement of profit and loss on Straight Line basis over the estimated useful lives of property, plant and equipment based on Schedule - II to the Companies Act, 2013 ("Schedule"), which prescribes the useful lives for various classes of tangible assets. For assets acquired or disposed off during the year, depreciation is provided on pro rata basis. Land is not depreciated.

Phyto Chem - Annual Report - 2020-21

Depreciation methods, useful lives and residual values are reviewed at the end of each reporting period with the effect of any changes in estimated useful lives residual values and impairment loss, if any, and are accounted for on a prospective basis.

Impairment of tangible and intangible assets other than goodwill:

At the end of each reporting period, the company reviews that carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss(if any). When it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual cash-generating units, or otherwise they are allocated to the smallest company of cash-generating units for which a reasonable and consistent allocation basis can be identified.

Intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment at least annually, and whenever there is an indication that the asset may be impaired.

Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cashflows are discounted to their present value using a pre tax discount rate that reflects current market assessments of the time value of the money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash -generating unit) is estimated to be less than its carrying amount , the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss.

When an impairment loss subsequently reverses, the carrying amount of the asset (or a cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss.

2.9 Financial Instruments:

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

A. Financial Assets:

i. Initial Recognition:

In the case of financial assets, not recorded at fair value through profit or loss (FVPL), financial assets are recognized initially at fair value plus transaction costs that are directly attributable to the acquisition of the financial asset. Purchases or Sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

ii. Subsequent Measurement:

For purposes of subsequent measurement, financial assets are classified in the following categories:

a. Financial Assets at Amortized Cost:

Financial assets are subsequently measured at amortized cost if these financial assets are held within a business model with an objective to hold these assets in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Interest income from these financial assets is included in finance income using the effective interest rate ("EIR") method. Impairment gains or losses arising on these assets are recognized in the Statement of Profit and Loss.



Phyto Chem (India) Limited

b. Financial Assets Measured at Fair Value:

Financial assets are measured at fair value through OCI if these financial assets are held within a business model with an objective to hold these assets in order to collect contractual cash flows or to sell these financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses, interest revenue and foreign exchange gains and losses which are recognized in the Statement of Profit and Loss. Investment in Equity Instruments are designated as Financial Assets measured at fair value through OCI and Investments in Mutual Funds are designated as Financial Assets measured at fair value through statement of Profit & Loss on date of transition.

c. Impairment of Financial Assets:

In accordance with Ind AS 109, expected credit loss (ECL) model for measurement and recognition of impairment loss on the trade receivables or any contractual right to receive cash or another financial asset that result from transactions that are within the scope of Ind AS 18. As Company trade receivables are realized within normal credit period adopted by the Company, hence the financial assets are not impaired.

d. De-recognition of Financial Assets:

The Company de-recognizes a financial asset only when the contractual rights to the cash flows from the asset expire, or it transfers the financial asset and substantially all risks and rewards of ownership of the asset to another entity. If the Company neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Company recognizes its retained interest in the assets and an associated liability for amounts it may have to pay. If the Company retains substantially all the risks and rewards of ownership of a transferred financial asset, the Company continues to recognize the financial asset and also recognizes a collateralized borrowing for the proceeds received.

B. Financial Liabilities:

Financial liabilities and equity instruments issued by the Company are classified according to the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument.

i. Initial Recognition:

Financial liabilities are classified, at initial recognition, as financial liabilities at FVPL, loans and borrowings and payables as appropriate. All financial liabilities are recognized initially at fair value and in the case of loans and borrowings and payables, net of directly attributable transaction costs. Fees of recurring nature are directly recognised in the statement of profit and loss as finance cost.

ii. Subsequent Measurement:

The measurement of financial liabilities depends on their classification, as described below:

a. Financial liabilities at FVPL:

Financial liabilities at FVPL include financial liabilities held for trading and financial liabilities designated upon initial recognition as at FVPL. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. Gains or Losses on liabilities held for trading are recognised in the Statement of Profit and Loss.

iii. De-recognition of Financial Liabilities:

Financial liabilities are de-recognised when the obligation specified in the contract is discharged, cancelled or expired. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as de-recognition of the original liability and recognition of a new liability. The difference in the respective carrying amounts is recognized in the Statement of Profit and Loss.

2.7 Impairment of non-financial assets:

Intangible assets and property, plant and equipment are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable amount (i.e. the higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the Cash Generated Units (CGU) to which the asset belongs. If such assets are considered to be impaired, the impairment to be recognized in the statement of profit and loss is measured by the amount by which the carrying value of the assets exceeds the estimated recoverable amount of the asset. An impairment loss is reversed in the statement of profit and loss if there has been a change in the estimates used to determine the recoverable amount. The carrying amount of the asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortization or depreciation) had no impairment loss been recognized for the asset in prior years.

2.10 Cash and Cash Equivalents:

Cash and Bank balances comprise of cash balance in hand, in current accounts with banks and Bank Fixed Deposits with maturity of 3 months or less than 3 months.

Cash flow Statement:

Cash flows are reported using the indirect method, where by profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payment and items of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the company are segregated.

2.11 Employee Benefits:

Short term employee benefits:

Short-term employee benefits are expensed as the related service is provided. A liability is recognised for the amount expected to be paid if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

Defined Contribution Plan:

The Company's contributions to defined contribution plans are charged to the statement of profit and loss as and when the services are received from the employees.

For defined benefit retirement benefit plans, the cost of providing benefits is determined using the projected unit credit method, with actuarial valuations being carried out at the end of each annual reporting period. Remeasurement, comprising actuarial gains and losses, the effect of the changes to the asset ceiling (if applicable) and the return on plan assets (excluding interest), is reflected immediately in the statement of financial position with a charge or credit recognised in other comprehensive income in the period in which they occur.

Defined Contribution Benefits:

The Company has an obligation towards gratuity, a defined benefit plan covering eligible employees. The plan provides for lump sum payment on retirement, death while in employment or on separation.

2.12 Borrowing Cost:

Borrowing costs are charged to the Statement of Profit and Loss except in cases where the borrowings are directly attributable to the acquisition, construction or production of qualifying assets which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale.



Phyto Chem (India) Limited

2.13 Government Grants:

Ind AS 20 gives an option to present the grants related to assets, including nonmonetary grants at fair value in the balance sheet either by setting up the grant as deferred income or by deducting the grant in arriving at the carrying amount of the asset. Accordingly Sales Tax Deferment amount payable to Department has been considered as Government Grant and considered the interest expenses and amortization benefit is considered in Profit and Loss Account and Balance Sheet.

2.14 Provisions, Contingent Liabilities and Contingent Assets:

A provision is recognized when the Company has a present obligation (legal or constructive) as a result of past events and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, in respect of which a reliable estimate can be made of the amount of obligation. Provisions (excluding gratuity and compensated absences) are determined based on management's estimate required to settle the obligation at the Balance Sheet date. In case the time value of money is material, provisions are discounted using a current pre-tax rate that reflects the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost. These are reviewed at each Balance Sheet date and adjusted to reflect the current management estimates.

Contingent liability judgement:

Contingent liabilities are claims against the company not acknowledged as debt. Contingencies may arise from the ordinary course of business in relation to claims against the Company, including legal, contractor and other claims. By their nature, contingencies will be resolved only when one or more uncertain future events occur. The assessment of the existence, and potential quantum of contingencies inherently involve the exercise of significant judgement and the use of estimates regarding the outcome of future events.

2.15 Estimates and assumptions:

The preparation of the Company's financial statements requires management to make judgements, estimates and assumptions that effect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities.

Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

Revenue recognition:

Revenue from contracts with customers which establishes a comprehensive framework for determining whether, how much and when revenue is to be recognised.

Revenue is measured at the fair value of the consideration received or receivable and is recognised when it is probable that the economic benefits associated with the transaction will flow to the Company and the amount of income can be measured reliably. Revenue is net of returns and is reduced for rebates, trade discounts, refunds and any other taxes collected on behalf of government such as GST etc.

Sale of goods:

Revenue is recognized when it is probable that economic benefits associated with a transaction flows to the Company in the ordinary course of its activities and the amount of revenue can be measured reliably. Revenue is recognised, when the significant risks and rewards of the ownership have been transferred to the buyers and there is no continuing effective control over the goods or managerial involvement with the goods. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes and duties.

Sale of services:

Revenue from rendering of services is recognised by measuring the progress towards complete satisfaction of performance obligations at the reporting period and there are no unfulfilled obligations.

Other Income:

Other income includes Dividend, Interest, Profit / (Loss) on sale of Investments, Commission, Professional and Technical Services and other miscellaneous receipts if any. Dividend income from investments is recognized when the Company's right to receive payment has been established (provided that it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably). Interest income from a financial asset is recognized when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on time proportionate basis, by reference to the principle outstanding and at the effective interest rate applicable. Commission income is recognised when the economic benefits associated with the transaction will flow to the entity or the amount of revenue can be measured reliably. When the transaction involving the rendering of services is estimated reliably, revenue associated with the transaction shall be recognised by reference to the stage of completion of the transaction at the end of the reporting period. The outcome of the transactions can be estimated reliably when all the following conditions are satisfied:(a) the amount of revenue can be measured reliably;(b) it is probable that the economic benefits associated with the transaction will flow to the entity;(c) the stage of completion of the transaction at the end of the reporting period can be measured reliably; and (d) the costs incurred for the transaction and the costs to complete the transaction can be measured reliably

2.16 Income Tax:

Current Tax

Current income tax is recognised based on the estimated tax liability computed after taking credit for allowances and exemptions in accordance with the Income Tax Act, 1961. Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date.

Deferred Tax

Deferred tax is determined by applying the Balance Sheet approach. Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. Such deferred tax assets and liabilities are not recognised if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Minimum Alternative Tax ("MAT") credit is recognised as an asset only when and to the extent there is convincing evidence that the company will pay normal income tax during the specified period. Such asset is reviewed at each Balance sheet date and the carrying amount of MAT credit asset is written down to the extent there is no longer a convincing evidence to the effect that the company will pay normal income tax during the specified period.

2.17 Earnings Per Share:

The Company presents basic and diluted earnings per share ("EPS") data for its ordinary shares. Basic earnings per share are computed by dividing the net profit after tax by the weighted average number of equity shares outstanding during the period. Diluted earnings per share is computed by dividing the profit after tax by the weighted average number of equity shares considered for deriving basic earnings per share and also the weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares.



Phyto Chem (India) Limited

2.18 Inventories:

Inventories are stated at the lower of cost and net realisable value. Costs of inventories are determined on a weighted average cost basis.

2.19 Trade Receivables:

Judgements are required in assessing the recoverability of overdue trade receivables and determining whether a provision against those receivables is required. Factors considered include the credit rating of the counter party, the amount and timings of anticipated future payments and any possible actions that can be taken to mitigate the risk of non-payment.

2.20 Trade and other payables:

These amounts represent liabilities for goods and services provided to the Company prior to the end of the financial year which are unpaid. The amounts are unsecured and are presented as current liabilities unless payment is not due within twelve months after the reporting period. They are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method.

2.21 Fair value of investments:

The Company has invested in the equity instruments of various companies. However, the percentage of shareholding of the company in such investee companies is very low and hence, it has not been provided with future projections including projected profit and loss account by those investee companies. Hence, the valuation exercise carried out by the company with the help of available historical annual reports and other information in the public domain.

Phyto Chem - Annual Report - 2020-21

Notes to Financial statements for the year ended 31st March 2021

(All amounts in Indian Rupees, except otherwise stated)

Note 3: Property, Plant & Equipment

Particulars	Land	Buildings	Plant & Equipment	Furniture & Fixtures	Vehicles	Office Equipment	Generator	Electrical Equipment	Lab Equipment	Computers	Total
Gross carrying amount											
Closing Gross carrying amount as at 31 st March 2019	730,705	32,366,917	19,207,457	1,557,211	9,666,805	590,213	121,232	1,341,262	1,689,823	385,133	67,656,758
Additions	-	7,379,349	59,000	52,127	1,462,759	100,289	-	-	-	18,850	9,072,374
Disposals	-	-	-	-	243,412	-	-	-	-	-	243,412
Closing Gross carrying amount as at 31 st March 2020	730,705	39,746,266	19,266,457	1,609,338	10,886,152	690,502	121,232	1,341,262	1,689,823	403,983	76,485,720
Additions	-	1,298,181	27,600	-	132,120	13,744	-	198,275	-	200,000	-
Disposals	-	11,281,500	-	-	859,463	-	-	-	-	-	-
Closing Gross carrying amount as at 31 st March 2021	730,705	29,762,947	19,294,057	1,609,338	10,158,809	704,246	121,232	1,539,537	1,689,823	603,983	66,214,676
Accumulated Depreciation											
Closing Accumulated Depreciation as at 31 st March 2019	-	10,027,112	8,105,807	904,346	3,728,283	312,500	22,145	883,217	1,650,854	217,799	25,852,062
Depreciation Charge during the year	-	1,025,709	1,269,067	172,000	1,285,138	114,173	7,382	104,701	5,178	112,669	4,096,016
Disposals	-	-	-	-	192,354	-	-	-	-	-	192,354
Closing Accumulated Depreciation as at 31 st March 2020	-	11,052,821	9,374,874	1,076,346	4,821,067	426,673	29,527	987,918	1,656,032	330,468	29,755,724
Depreciation Charge during the year	-	1,145,976	1,270,815	172,000	1,297,689	116,784	7,382	123,537	5,178	119,002	4,258,363
Disposals	-	1,295,025	-	-	847,973	-	-	-	-	-	2,142,998
Closing Accumulated Depreciation as at 31 st March 2021	-	10,903,772	10,645,689	1,248,346	5,270,783	543,457	36,909	1,111,455	1,661,210	449,470	31,871,089
Net Carrying Value as at 31 st March 2020	730,705	28,693,446	9,891,583	532,992	6,065,085	263,829	91,706	353,344	33,791	73,515	46,729,996
Net Carrying Value as at 31 st March 2021	730,705	18,859,175	8,648,368	360,992	4,888,026	160,789	84,324	428,082	28,613	154,513	34,343,587

Note:

- a. All the Titles of the Properties are existed in the name of the Company.
- b. Depreciation is calculated as per Straight Line Method based on useful life of assets as indicated in Schedule-II of the Companies Act, 2013.
- c. All Properties, Plant and Equipments are under Charge created by the Company for the Term loans availed.



Phyto Chem (India) Limited

Notes to financial statements for the year ended 31st March 2021

(All amounts in Indian Rupees, except otherwise stated)

Financial assets

Note 4: Non-current Investments

Particulars	As at 31 st March 2021	As at 31 st March 2020
Investment in Equity shares		
I. Investments in equity Instruments at fair value through other comprehensive income (fully paid)		
A. Quoted & Non-Trade		
Anjani Portland Cement Ltd. 3,700 (March 31, 2020: 3,700) Equity shares of Rs.10/- each	782,180	348,910
Alok Industries Ltd. 1,000 (March 31, 2020: 1,000) Equity shares of Rs.10/- each	20,150	3,920
Ginni Filaments Ltd. 1,000 (March 31, 2020: 1,000) Equity shares of Rs.10/- each	19,650	6,040
Bheema Cements Ltd. 70,000 (March 31, 2020: 70,000) Equity shares of Rs.10/- each	637,000	637,000
Silver Line Technologies Ltd. 120 (March 31, 2020: 120) Equity shares of Rs.10/- each	263	263
Computech International Ltd. 5,000 (March 31, 2020: 5,000) Equity shares of Rs.10/- each	8,200	8,200
Next Animation Media Ltd. 48 (March 31, 2020: 48) Equity shares of Rs.10/- each	85	85
Total equity Investments (Quoted) (A)	1,467,528	1,004,418
B. Unquoted & Trade		
Jeedimetla Effluent Treatment Ltd. 500 (March 31, 2020: 500) Equity shares of Rs.10/- each	50,000	50,000
Total equity Investments (Unquoted) (B)	50,000	50,000
Total equity Investments (A+B) - I	1,517,528	1,054,418
II. Investments in Others		
Investments in Government Securities (at amortised cost)		
Unquoted & Non-Trade		
i. Investments in Government Securities	65,400	65,400
Total investments in Government Securities - II	65,400	65,400
Total Non-current Investments (I+II)	1,582,928	1,119,818
Aggregate amount of quoted investments and market value thereof	1,467,528	1,004,418
Aggregate amount of unquoted investments	115,400	115,400
Aggregate amount of impairment in the value of Investments	-	-

Note 5: Loans

Particulars	As at 31 st March 2021	As at 31 st March 2020
Staff advances	1,938,965	2,723,965
Total	1,938,965	2,723,965

Note 6: Other non-current financial assets

Particulars	As at 31 st March 2021	As at 31 st March 2020
Security Deposits	1,368,454	1,319,494
GST credit receivable	785,837	1,433,490
Rental deposits	191,546	191,546
Other advances	1,764,272	1,502,980
Total	4,110,109	4,447,510

Phyto Chem - Annual Report - 2020-21

Notes to financial statements for the year ended 31st March 2021

(All amounts in Indian Rupees, except otherwise stated)

Current assets

Note 7: Inventories

Particulars	As at 31 st March 2021	As at 31 st March 2020
Raw materials	40,563,339	64,871,521
Finished goods	92,174,009	76,834,273
Packing materials	18,808,116	16,952,269
House plots	9,679,000	9,679,000
Total	161,224,463	168,337,063

Valuation

- a. Raw materials, Packing materials and Residential plots are valued at lower of cost or net realisable value.
- b. Finished goods are valued at cost conversion and other costs incurred in bringing the inventories to their present location and condition or net realisable value whichever is lower.

Financial assets - current

Note 8: Trade receivables

Particulars	As at 31 st March 2021	As at 31 st March 2020
Unsecured and considered good	222,889,801	436,522,239
Unsecured and considered doubtful	-	-
	222,889,801	436,522,239
Expected Credit Loss Allowance (allowance for bad and doubtful debts)	-	-
Total Trade receivables	222,889,801	436,522,239

- a. The Average Credit period on sales is 180 days.
- b. No Trade or other receivables are due from directors or other officers of the Company.
- c. No trade or other receivables are due from firms or private companies respectively in which any director is a partner or director.

Aging of receivables

Particulars	As at 31 st March 2021	As at 31 st March 2020
Within credit period (upto 180 days due)	110,239,315	184,947,706
more than 180 days past due	112,650,486	251,574,533
Total trade receivables (before impairment allowance)	222,889,801	436,522,239

Note 9: Cash and cash equivalents

Particulars	As at 31 st March 2021	As at 31 st March 2020
Balances with banks in Current Account	421,066	261,114
Cash on Hand	195,003	232,376
Total	616,069	493,490

Note 10: Bank balances other than Cash and cash equivalents

Particulars	As at 31 st March 2021	As at 31 st March 2020
Balances with banks	-	-
LC-Margin deposit with bank	-	-
Balances with banks in Current Account earmarked for dividend	643,888	1,310,561
Total	643,888	1,310,561



Phyto Chem (India) Limited

Notes to financial statements for the year ended 31st March 2021

(All amounts in Indian Rupees, except otherwise stated)

Note 11: Other current assets

Particulars	As at 31 st March 2021	As at 31 st March 2020
Advances other than Capital Advances:		
i. Security Deposits	-	-
ii. Advances to related parties	-	-
iii. Other Advances		
A. Advance for Raw Materials	15,399,460	11,665,319
B. Deposits & Other Advances	8,542,583	2,550,094
Total	23,942,043	14,215,413

Equity

Equity share capital and other equity

Note 12: Equity share capital

Particulars	As at 31 st March 2021	As at 31 st March 2020
(a) Authorised share capital:		
1,35,00,000 equity shares of Rs.10/- each (As at 31 st March 2020 1,35,00,000 equity shares)	135,000,000	135,000,000
(b) Issued:		
43,02,000 equity shares of Rs.10/- each (As at 31 st March 2020 43,02,000 equity shares)	43,002,000	43,002,000
(c) Subscribed and fully paid:		
43,02,000 equity shares of Rs.10/- each (As at 31 st March 2020 43,02,000 equity shares)	43,002,000	43,002,000
Total	43,002,000	43,002,000

Reconciliation of the number of equity shares outstanding

Particulars	As at 31 st March 2021	As at 31 st March 2020
At the beginning of the year	4,300,200	4,300,200
Add: Issued during the year	Nil	Nil
Less: Cancelled during the year	Nil	Nil
At the end of the year	4,300,200	4,300,200

Terms/ Rights attached to Equity shares:

The Company has one class of equity shares having a par value of Rs.10/- per share. Each shareholder is entitled to one vote per share held. In the event of liquidation of the Company, the shareholders of equity shares will be entitled to receive the remaining assets of the Company, after distribution of all preferential amounts, in proportion to the number of equity shares held by the shareholders.

Details of shareholders holding more than 5% of aggregate shares in the Company

Particulars	As at 31 st March 2021 % of holding	As at 31 st March 2020 % of holding
i. Mr.Y.Nayudamma: No.of shares - 3,38,306 (As at 31 st March 2020 3,38,306 equity shares)	7.87%	7.87%

Phyto Chem - Annual Report - 2020-21

Notes to financial statements for the year ended 31st March 2021

(All amounts in Indian Rupees, except otherwise stated)

Note 13: Other equity

Particulars	See Note below	As at 31 st March 2021	As at 31 st March 2020
Retained earnings	(i)	23,709,646	19,879,237
Other reserve	(ii)	36,010,837	36,010,837
Reserve for other comprehensive income items	(iii)	(877,280)	(414,170)
Total		58,843,203	55,475,904

Reserves and surplus

(i) Retained earnings

Particulars	As at 31 st March 2021	As at 31 st March 2020
Balance at the beginning of the year	19,879,237	15,735,351
Net profit for the period	4,930,542	4,457,352
Payment of Dividend and Dividend distribution tax	-	-
Transfer to General Reserve	-	-
Others- adjustment for gratuity fund	(2,060,718)	-
Other comprehensive income	960,585	(313,467)
Total	23,709,646	19,879,237

(ii) Other reserves

General Reserve

Particulars	As at 31 st March 2021	As at 31 st March 2020
Balance at the beginning of the year	36,010,837	36,010,837
Add: Transfer from surplus in statement of profit & loss	-	-
Closing balance	36,010,837	36,010,837

(iii) Reserve for other comprehensive income items

Particulars	As at 31 st March 2021	As at 31 st March 2020
Other comprehensive income arising from actuarial gain/loss on defined benefit obligation (Net of taxes)	(414,170)	(522,795)
Balance at the beginning of the year	(463,110)	108,625
Gains/(losses) on arising from actuarial gain/loss on gratuity	-	-
Closing balance	(877,280)	(414,170)

Financial liabilities

Note 14: Borrowings

Particulars	As at 31 st March 2021	As at 31 st March 2020
A. Non-current borrowings		
Secured		
Term Loans		
From banks	27,276,990	19,052,340
For vehicles from bank	168,286	904,513
Unsecured		
Unsecured sales tax deferment loan (Commercial tax department)		
Sales tax deferment loan	4,938,246	6,806,317
Deferred revenue grant	3,875,416	4,510,093
Total (taken to Non-current liabilities in Balance sheet)	36,258,938	31,273,263
B. Current borrowings		
From banks		
Secured		
Working capital demand loans (Cash Credit)	156,443,792	170,021,627
Loans from others - From related parties		
Unsecured		
Unsecured Loans from Directors	-	19,611,071
Total (taken to Current liabilities in Balance sheet)	156,443,792	189,632,698

There is no default as at 31st March 2021 as well as 31st March 2020 in repayment of loans and interest payments on Banks.



Phyto Chem (India) Limited

Notes to financial statements for the year ended 31st March 2021

(All amounts in Indian Rupees, except otherwise stated)

Terms of Repayment

Particulars	As at 31 st March 2021	As at 31 st March 2020
A. Term loans:		
(a) Monthly EMI of Rs.1,54,332/- payable up to September 2035, ROI @ 12.60% p.a	-	28,669,371
(b) Monthly EMI of Rs.6,63,507/- payable up to March 2022, ROI @ 10.25% p.a	-	15,924,178
(c) Monthly EMI of Rs.10,53,235/- payable up to August 2024, ROI @ 9.25% p.a	37,916,460	-
B. Vehicle loans :		
(a) Monthly EMI of Rs.28,579/- payable up to June 2021, ROI @ 8.90% p.a	85,737	428,685
(b) Monthly EMI of Rs.28,725/- payable up to July 2021, ROI @ 9.25% p.a	114,900	459,600
(c) Monthly EMI of Rs.19,053/- payable up to June 2021, ROI @ 8.90% p.a	57,159	285,795
(d) Monthly EMI of Rs.19,541/- payable up to December 2021, ROI @ 9.50% p.a	175,869	410,361
(e) Monthly EMI of Rs.28,830/- payable up to September 2022, ROI @ 9.50% p.a	518,940	864,900

Security:

- (a) Term loan from banks are secured by exclusive charge on specific assets.
- (b) The loan repayable on demand from banks are cash credits, bills purchase, discountings, letter of credits limits and bank guarantees are secured by Hypothecation of Raw-material, Stock in progress, Finished goods, Consumable spares, Book debts and receivables.
- (c) The working capital and Term loans from banks are also secured by first and second charge on some of the fixed assets of the Company.
- (d) The working capital and Term loans are further secured by guarantee from a Director and a Promoter in individual capacities.

Note 15: Other non-current financial liabilities

Particulars	As at 31 st March 2021	As at 31 st March 2020
Security Deposits from dealers	12,219,445	12,429,489
Total	12,219,445	12,429,489

Note 16: Deferred tax liabilities

Particulars	As at 31 st March 2021	As at 31 st March 2020
-------------	--------------------------------------	--------------------------------------

The balances comprises temporary differences attributable to:

Deferred tax liabilities

Duties on stocks	-	-
Other comprehensive income	(107,441)	78,552
Depreciation and amortisation	1,158,958	2,756,252

Less:

Deferred tax assets

Expenses allowable on payment basis	4,288,219	3,873,453
Other comprehensive income	67,871	29,814

Net deferred tax liability/(asset)

	(3,304,573)	(1,068,463)
--	--------------------	--------------------

Reconciliation of net deferred tax liabilities

Particulars	As at 31 st March 2021	As at 31 st March 2020
Opening Balance at the beginning of the year	(1,068,463)	417,933
Recognised in statement of Profit and Loss during the year	(2,165,456)	(1,581,107)
Recognised in Other Comprehensive Income during the year	(70,655)	94,711
Closing Balance as at the end of the year	(3,304,573)	(1,068,463)

Phyto Chem - Annual Report - 2020-21

Notes to financial statements for the year ended 31st March 2021

(All amounts in Indian Rupees, except otherwise stated)

Current liabilities

Financial liabilities

Note 17: Trade payables

Particulars	As at 31 st March 2021	As at 31 st March 2020
Sundry creditors - Less than 12 months		
A. Total outstanding dues of Micro, Small & Medium Enterprises (See Note No. 43)	-	-
B. Total outstanding dues other than Micro, Small & Medium Enterprises	103,101,862	311,308,036
Total	103,101,862	311,308,036

Note 18: Other current financial liabilities

Particulars	As at 31 st March 2021	As at 31 st March 2020
Current maturities of long term debt	20,956,220	8,862,582
Unclaimed dividend - F.Y 2012-13 (Transferred to IEPF during the year)	-	666,673
Unclaimed dividend - F.Y 2013-14	643,888	643,888
Total	21,600,108	10,173,143

Note 19: Other current liabilities

Particulars	As at 31 st March 2021	As at 31 st March 2020
Advances from customers	8,703,650	12,461,231
Statutory dues towards GST, TDS etc	3,307,811	1,049,546
Other current liabilities	77,590	662,943
Total	12,089,051	14,173,720

Note 20: Short-term provisions

Particulars	As at 31 st March 2021	As at 31 st March 2020
Employee benefits	6,753,668	7,544,125
Provision for Gratuity	2,384,359	606,140
Total	9,138,027	8,150,265

Note 21: Current tax liability (asset) (net)

Particulars	As at 31 st March 2021	As at 31 st March 2020
Current tax liability		
Provision for Income tax	1,900,000	1,350,000
Total	1,900,000	1,350,000

Note 22: Revenue from operations

Particulars	Year ended 31 st March 2021	Year ended 31 st March 2020
Sale of Pesticides (Gross)	523,932,631	521,044,538
Sale of services (Gross)	368,784	-
Less: GST (Goods & Services Tax)	79,421,092	78,816,649
Total	444,880,323	442,227,889

Note 23: Other income

Particulars	Year ended 31 st March 2021	Year ended 31 st March 2020
Bad debts recovered	31,950	853,143
Income received on chit contributions	1,533,500	130,500
Exchange fluctuation gain	3,036,112	12,829,629
Interest received	7,507	-
Profit on sale of assets	3,413,372	12,397
Miscellaneous Income	24,400	-
Total	8,046,841	13,825,669



Phyto Chem (India) Limited

Notes to financial statements for the year ended 31st March 2021

(All amounts in Indian Rupees, except otherwise stated)

Note 24: Cost of Materials Consumed

Particulars	Year ended 31 st March 2021	Year ended 31 st March 2020
A. Raw Materials Consumed :		
Opening Stock	64,871,521	55,027,747
Add : Purchases	307,140,092	319,113,819
Customs Duty	19,364,984	16,284,799
Freight Inward	2,332,502	2,630,283
Import Clearing Charges	3,206,357	1,194,306
	396,915,455	394,250,953
Less : Closing Stock	40,563,339	64,871,521
Total A - Raw Materials Consumed	356,352,116	329,379,433
B. Packing Materials Consumed		
Opening Stock	16,952,269	19,920,343
Add : Purchases	14,157,325	13,143,133
	31,109,594	33,063,476
Less : Closing Stock	18,808,116	16,952,269
Total B - Packing Materials Consumed	12,301,478	16,111,207
Total A+B - Cost of Materials Consumed	368,653,594	345,490,640

Note 25: Changes in inventories of finished goods, land and work in progress

Particulars	Year ended 31 st March 2021	Year ended 31 st March 2020
A. Opening inventory		
i. Finished goods	76,834,273	83,518,706
ii. House plots	9,679,000	9,679,000
Total opening stock	86,513,273	93,197,706
B. Closing inventory		
i. Finished goods	92,174,009	76,834,273
ii. House plots	9,679,000	9,679,000
Total closing stock	101,853,009	86,513,273
Total changes in inventories of finished goods, land and work in progress	(15,339,735)	6,684,432

Note 26: Employee benefit expense

Particulars	Year ended 31 st March 2021	Year ended 31 st March 2020
Salaries, Wages, Bonus and allowances	29,004,970	31,481,507
Contribution to ESI, Provident Fund	2,138,031	2,459,415
Gratuity	361,584	606,140
Staff Welfare expenses	587,897	953,172
Total	32,092,482	35,500,234

Phyto Chem - Annual Report - 2020-21

Notes to financial statements for the year ended 31st March 2021

(All amounts in Indian Rupees, except otherwise stated)

Note 27: Finance cost

Particulars	Year ended 31 st March 2021	Year ended 31 st March 2020
Interest on bank loans	20,570,860	23,625,403
Other borrowing costs	596,949	1,068,553
Total	21,167,809	24,693,956

Note 28: Other expense

Particulars	Year ended 31 st March 2021	Year ended 31 st March 2020
Power and fuel	933,044	1,062,010
Rent	1,712,356	1,686,664
Factory maintenance	1,011,513	1,218,684
Lab consumables	18,325	18,066
Safety devices	96,675	88,553
First aid and medical expenses	93,048	4,264
Samples	14,185	-
Insurance	500,094	334,524
Rates and taxes	286,152	1,160,965
Selling and distribution expenses	19,212,196	6,987,822
Licence and fees	547,194	640,158
Statutory audit fee (Refer Note 29)	100,000	100,000
Office expenses	614,663	584,732
Petrol and diesel	431,487	447,623
Printing and stationery	181,634	258,963
Telephone charges	345,931	469,746
Vehicle maintenance	247,514	563,869
Administration expenses	2,602,260	3,306,473
Exchange fluctuation	2,982,342	8,437,470
Social welfare surcharge	1,895,037	1,627,906
Travelling expenses	3,603,915	6,363,544
Total	37,429,565	35,362,034



Phyto Chem (India) Limited

Notes to financial statements for the year ended 31st March 2021

(All amounts in Lakhs, except otherwise stated)

Note 29: Auditors remuneration

Particulars	For the year ended 31 st March 2021	For the year ended 31 st March 2020
Statutory audit fee (see Note 28)	100,000	100,000
Reimbursement of out of pocket expenses	-	-
Total	100,000	100,000

Note 30: Earnings per share

Particulars	For the year ended 31 st March 2021	For the year ended 31 st March 2020
Earnings		
Profit attributable to equity holder	4,930,542	4,457,352
Shares		
Number of shares at the beginning of the year	4,300,200	4,300,200
Add: Equity Shares issued	-	-
Less: Buy back of Equity shares	-	-
Total number of equity shares outstanding at the end of the year	4,300,200	4,300,200
Weighted average number of equity shares outstanding during the year – Basic	4,300,200	4,300,200
Add: Weighted average number of equity shares arising out of outstanding stock options (net of the stock options forfeited) that have dilutive effect on the EPS	-	-
Weighted average number of equity shares outstanding during the year – Diluted	4,300,200	4,300,200
Earnings per share of par value Rs.10/- – Basic	1.15	1.04
Earnings per share of par value Rs.10/- – Diluted	1.15	1.04

Note 31: Related party disclosures

In accordance with the provisions of Ind AS 24 “Related Party Disclosures” and the Companies Act, 2013, Company’s Directors, members of the Company’s Management and Key Management Personnel are considered. List of related party of the Company is as below:

A. Names of related parties and description of relationship:

Description of relationship	Name of related party
Key Management Personnel	Mr. Y. Nayudamma - Managing Director Mr. Y. Janaki Ramaiah - Executive Director Mr. Pavansingh Thakur - Company Secretary Mr. B. Sambasiva Rao - Chief Financial Officer (w.e.f. 01-04-2019)
Directors	Dr. P. Sreemannarayana - Chairman Mr. Y. Nayudamma - Executive Director Mr. Y. Janaki Ramaiah - Executive Director Mr. Y. Venkateswarlu - Non-Executive Director Mr. K. Srinivasa Rao (Alternate Director to Mr. Y. Venkateswarlu) - Non-Executive Director Mr. P. Anjaneyulu - Non-Executive Director Mr. T. A. Choudary - Independent Director (upto 12-11-2020) Mrs. S. Kavitha Rani - Independent Director (upto 12-11-2020) Mr. N. Sudhakar - Independent Director (upto 12-11-2020) Dr. G.S.R. Anjaneyulu - Independent Director Mr. M. Sree Ram Murthy - Independent Director Mr. K. Ravindra Babu - Independent Director (w.e.f. 28-12-2020) Mr. S. Y. Sampath Kumar - Independent Director (w.e.f. 28-12-2020) Mrs. G. Vijitha - Independent Director (w.e.f. 28-12-2020)
Relatives of KMP	Mr. Y. Sreemannarayana - Son of Managing Director

Phyto Chem - Annual Report - 2020-21

Notes to financial statements for the year ended 31st March 2021

(All amounts in Lakhs, except otherwise stated)

B. Related party transactions with the above related parties is as follows:

Sl.No	Nature of the transaction	During the financial year 2020-21	During the financial year 2019-20	Balance Outstanding as on 31-03-2021	Balance Outstanding as on 31-03-2020
1	Remuneration:				
	Mr. Y. Nayudamma, Managing Director	3,499,920	2,799,220	83,000	275,163
	Mr. Y. Janaki Ramaiah, Executive Director	1,743,703	1,842,075	38,365	84,293
	Mr. Pavansingh Thakur, Company Secretary	675,909	503,046	52,760	-
	Mr. B. Sambasiva Rao, Chief Financial Officer	419,796	389,338	33,020	-
2	Sitting fees for attending Board/ Committee meetings :				
	Mr. T. A. Choudary (upto 12-11-2020)	22,500	40,000	-	-
	Mrs. S. Kavitha Rani (upto 12-11-2020)	22,500	40,000	-	-
	Mr. N. Sudhakar (upto 12-11-2020)	6,500	45,000	-	-
	Dr. G. S. R. Anjaneyulu	40,000	40,000	-	-
	Mr. M. Sree Ram Murthy	32,000	26,000	-	-
	Mr. K. Ravindra Babu (w.e.f. 28-12-2020)	25,500	-	-	-
	Mr. S. Y. Sampath Kumar (w.e.f. 28-12-2020)	25,500	-	-	-
	Mrs. G. Vijitha (w.e.f. 28-12-2020)	20,500	-	-	-
3	Unsecured loans taken from related parties:				
	Repayment of Loans to Directors	18,532,602	14,915,073	-	-
	Repayment of Interest on Loans to Directors	1,078,469	3,881,665	-	-
	Outstanding Balance due to Directors	-	-	-	19,611,071
4	Relatives of KMP:				
	Mr. Y. Sreemannarayana, Son of Managing Director				
	Salary paid	221,614	-	43,240	-
	Rent paid for office premises	638,880	638,880	-	47,916
5	Investment in the Company (at face value):				
	Mr. Y. Nayudamma, Managing Director	-	-	3,383,060	3,383,060
	Mr. Y. Janaki Ramaiah, Executive Director	-	-	973,720	973,720
	Mr. Pavansingh Thakur, Company Secretary	-	-	-	-
	Mr. B. Sambasiva Rao, Chief Financial Officer	-	-	157,000	157,000
	Mr. T. A. Choudary, Independent Director (upto 12-11-2020)	-	-	840	840
	Mr. Y. Sreemannarayana, Son of Managing Director	-	694,110	1,020,110	1,020,110

Note 32: Segment Reporting

Ind AS 108 establishes standards for the way that public business enterprises report information about operating segments and related disclosures about products and services. Based on the 'Management' approach as defined under Ind AS108, the Chief Operating Decision Maker (CODM) evaluates the performance on a periodical basis and allocates resources based on an analysis of the performance of various Businesses. The CODM is the Managing Director. The accounting principles used in the preparation of the financial statements are consistently applied to record revenue and expenditure in individual segments and are as set out in the Significant Accounting Policies. Since the Company operates mainly in one segment i.e. Manufacturing and Marketing of pesticides formulations, reporting of segment revenue and results does not arise. There are no operations in other business activity i.e. Real estate during the year under review.



Phyto Chem (India) Limited

Notes to financial statements for the year ended 31st March 2021

(All amounts in Lakhs, except otherwise stated)

Note 33: Employee benefits

Disclosure pursuant to Ind AS 19.

The following table sets out the amounts recognised in the financial statements in respect of gratuity plan.

Particulars	Year ended 31 st March 2021	Year ended 31 st March 2020
1. Change in defined benefit obligations		
Present value at the beginning of the year	4,701,150	3,888,960
Current service cost	361,584	452,148
Interest cost	340,833	291,672
Remeasurement (gains)/losses	(73,934)	204,582
Past service cost	-	-
Benefits paid	(82,384)	(136,212)
Present Value at the end of the year	5,247,249	4,701,150
2. Changes in fair value of planned assets		
Fair value of plan assets at the beginning of the year	2,206,716	1,481,410
Investment income	168,409	137,680
Employer's contributions	570,149	723,838
Benefits paid	(82,384)	(136,212)
Return on plan assets, excluding amount recognised in net interest expense	-	-
Fair value of plan assets at the end of the year	2,862,890	2,206,716
3. Amount recognised in the balance sheet		
Present value of defined obligations at the end of year	5,247,249	4,701,150
Fair value of plan assets at the end of year	2,862,890	2,206,716
Net asset/(liability) recognised in balance sheet	(2,384,359)	(2,494,434)
4. Expenses recognised in statement of Profit and Loss		
Current service cost	361,584	452,148
Past service cost	-	-
Net interest expenses	340,833	291,672
Other comprehensive income: (Gain)/Loss on plan assets	(168,409)	(137,680)
5. Amount recognised in Other Comprehensive Income		
Actuarial (gain)/loss arising from changes in financial assumptions	-	167,219
Actuarial (gain)/loss arising from changes in experience adjustments	(73,934)	37,363
Expenses recognised in the statement of profit and loss	(73,934)	810,721
6. Actuarial assumptions		
Discount rate (per annum)	7.00%	7.25%
Salary growth rate (per annum)	6.00%	7.00%

Note 34: Income taxes

A. Income tax expense / (benefit) recognized in the statement of profit and loss:

i. Income tax expense/ (benefit) recognized in the statement of profit and loss consists of the following:

Particulars	For the year ended 31 st March 2021	For the year ended 31 st March 2020
Current tax expense:		
Domestic	1,900,000	1,350,000
Deferred taxes expense/(benefit):		
Domestic	2,165,456	1,581,107
Total income tax expense/(benefit) recognized in the statement of profit and loss	4,065,456	2,931,107

Phyto Chem - Annual Report - 2020-21

Notes to financial statements for the year ended 31st March 2021

(All amounts in Lakhs, except otherwise stated)

ii. Reconciliation of tax expenses and the accounting profit multiplied by tax rate

Particulars	For the year ended 31 st March 2021	For the year ended 31 st March 2020
Profit before Income tax expense	4,665,086	4,226,246
Tax at the Indian tax rate of 22.90%	1,068,305	967,810
Effect of non-deductible expense	1,713,305	1,552,245
Effect of deductible expense	(1,006,241)	(1,269,752)
Interest on delayed payment of Advance tax (Sec.234B&C)	209,331	99,697
TDS/TCS receivable / Advance tax paid	(84,700)	-
	1,900,000	1,350,000

B. Deferred tax assets & liabilities:

The tax effects of significant temporary differences that resulted in deferred tax assets and liabilities and a description of the items that created these differences is given below:

Particulars	For the year ended 31 st March 2021	For the year ended 31 st March 2020
Opening balance at the beginning of the year	(1,068,463)	417,933
Recognised in the statement of profit and loss during the year	(2,165,456)	(1,581,107)
Recognised in other comprehensive income during the year	(70,655)	94,711
Net deferred tax assets/(liabilities)	(3,304,573)	(1,068,463)

C. Movement in deferred tax assets and liabilities during the year ended 31st March 2021 & 2020:

Particulars	As at 1 st April 2019	Recognised in statement of profit and loss	Recognised in equity (OCI)	As at 31 st March 2020
Deferred tax assets/(liabilities)				
Property, plant and equipment - liability	4,459,996	(1,325,729)	-	2,756,252
Others	(4,042,062)	(255,377)	94,711	(4,202,729)
Net deferred tax assets/(liabilities)	417,933	(1,581,107)	94,711	(1,068,463)
Particulars	As at 1 st April 2019	Recognised in statement of profit and loss	Recognised in equity (OCI)	As at 31 st March 2020
Deferred tax assets/(liabilities)				
Property, plant and equipment - liability	2,756,252	(1,750,690)	-	1,158,957
Others	(4,202,729)	(414,766)	(70,655)	(4,668,150)
Net deferred tax assets/(liabilities)	(1,068,463)	(2,165,456)	(70,655)	(3,304,573)

Note 35: Investments

Investments consist of investments in Mutual funds, Bonds, Preference Shares and Debentures measured at Fair value through Profit & Loss Account and investment in equity instruments measured at Fair Value through Other Comprehensive Income.



Phyto Chem (India) Limited

Notes to financial statements for the year ended 31st March 2021

(All amounts in Lakhs, except otherwise stated)

The details of such Investments in equity as on 31st March 2021 are as follows:

Particulars	Fair value as on 1 st April 2020	Disposal of Investments during the year	Gain recognised directly in equity (OCI)	Fair value as on 31 st March 2021
Non - current investments	-	-	-	-
Investments in equity	1,119,818	-	463,110	1,582,928
Total	1,119,818	-	463,110	1,582,928

The details of such Investments in equity as on 31st March 2020 are as follows:

Particulars	Cost	Gain recognised directly in equity	Gain recognised directly in profit and loss account	Fair value
Non - current investments	-	-	-	-
Investments in equity	1,228,443	-	(108,625)	1,119,818
Total	1,228,443	-	(108,625)	1,119,818

Financial instruments:

Set out below, is a comparison by class of the carrying amounts and fair value of the financial instruments, other than those with carrying amounts that are reasonable approximations of fair values:

Particulars	Carrying value		Fair value	
	Mar-21	Mar-20	Mar-21	Mar-20
Financial assets:				
Trade receivables	222,889,801	436,522,239	222,889,801	436,522,239
Cash and cash equivalents	616,069	493,490	616,069	493,490
Bank balances other than cash and cash equivalents	643,888	1,310,561	643,888	1,310,561
Non-current assets- Loans and advances	6,049,074	7,171,475	6,049,074	7,171,475
Current assets- Other current assets	23,942,043	14,215,413	23,942,043	14,215,413
Total	254,140,875	459,713,178	254,140,875	459,713,178
Financial Liabilities:				
Non-current liabilities-Other financial liabilities	12,219,445	12,429,489	12,429,489	12,429,489
Borrowings	192,702,730	220,905,961	192,702,730	220,905,961
Trade payables	103,101,862	311,308,036	103,101,862	311,308,036
Other financial liabilities	21,600,108	10,173,143	21,600,108	10,173,143
Total	329,624,145	554,816,629	329,624,145	554,816,629

The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable and consists of the following three levels:

- Level 1 — Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 — Inputs are other than quoted prices included within Level 1 that are observable for the Asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices).
- Level 3 — Inputs are not based on observable market data (unobservable inputs). Fair values are determined in whole or in part using a valuation model based on assumptions that are neither supported by prices from observable current market transactions in the same instrument nor are they based on available market data.

Phyto Chem - Annual Report - 2020-21

Notes to financial statements for the year ended 31st March 2021

(All amounts in Lakhs, except otherwise stated)

Note 36: Financial risk management

The Company's activities expose it to a variety of financial risks, including credit risk, liquidity risk and Market risk. The Company's risk management assessment and policies and processes are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor such risks and compliance with the same. Risk assessment and management policies and processes are reviewed regularly to reflect changes in market conditions and the Company's activities. The Board of Directors and the Audit Committee is responsible for overseeing the Company's risk assessment and management policies and processes.

a. Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the credit worthiness of customers to which the Company grants credit terms in the normal course of business.

Trade receivables - The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the credit worthiness of customers to which the Company grants credit terms in the normal course of business. On account of adoption of Ind AS 109, the Company uses Expected Credit Loss (ECL) model for assessing the impairment loss. As Company trade receivables are realised within normal credit period adopted by the company, the financial assets are not impaired.

Financial assets that are neither past due nor impaired - None of the Company's cash equivalents, including deposits with banks, were past due or impaired as at 31st March 2021.

b. Liquidity risks

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risk to the Company's reputation.

As of 31st March 2021 and 2020, the Company had unutilized credit limits from banks of Rs. NIL and Rs. NIL respectively.

As of 31st March 2021, the Company had working capital (current assets less current liabilities) of Rs.10,50,43,424/- including cash and cash equivalents and Bank balances other than cash and cash equivalents of Rs.12,59,957/-, as against the Company's working capital of Rs.8,60,90,904/- as on 31st March 2020 including cash and cash equivalents and Bank balances other than cash and cash equivalents of Rs.18,04,051/-.

c. Market risks

Market risk is the risk that changes in market prices such as commodity prices risk, foreign exchange rates and interest rates which will affect the Company's financial position. Market risk is attributable to all market risk sensitive financial instruments. Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market Risk comprises three types of risk: Interest Rate Risk, Foreign Currency Risk and Commodity Risk.

d. Interest rate risks

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in Market Interest Rates. The Company is not having any debt obligation with floating interest rates.



Phyto Chem (India) Limited

Notes to financial statements for the year ended 31st March 2021

(All amounts in Lakhs, except otherwise stated)

e. Foreign currency risks

Foreign currency risk is the risk that the fair value of future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Company is not having any debt obligations with floating interest rates.

f. Commodity price risks

The Commodity Price risk is affected by the price volatility of certain commodities. The Company is not having any exposure for any commodity.

Note 37: Capital management

The Company's objective for capital management is to maximize shareholder wealth, safeguard business continuity and support the growth of the Company. The Company determines the capital management requirement based on annual operating plans and long term plans. The funding requirements are met through equity, borrowings and operating cash flows required. The Company's capital comprises Equity Share Capital, Retained Earnings and other equity attributable to equity holders.

Note 38:

No amount is due or payable by any of the directors, firms, private companies in which any Director is a partner / director / manager or companies under the same management towards sundry debtors / loans and advances in the Company. Maximum amount outstanding from the above - Nil (Nil).

Note 39: Contingent liabilities

a. Claims against the Company not acknowledged as debt:

- The Company has appealed against the decision of CTO for the improper addition of turnovers for the Financial Years 2010-11, 2011-12 & 2012-13. The Appeal filed by the Company was remanded back by the Appellate Authority in favour of the Company and the matter is pending before the regular CTO. The disputed tax in respect of this appeal is Rs.10,21,615/-. Since the management is hopeful to get favourable decision, no provision is made in the books of accounts.
- Outstanding demand from the Income Tax Department is Rs.1,71,935/-, which is not paid by the Company.

b. Bank guarantees: Nil

Note 40:

Amount payable to Sales tax department towards Deferment of Rs.87,45,791.

In view of Ind AS adjustment, the said amount is shown as under:

Particulars	Amount in Rs.
Amount payable to Sales tax department:	8,745,791
Add / (Less): Amount transferred to fair value: (Difference between Amortisation Income & Expenditure)	67,871
Total	8,813,662
Unsecured Sales tax deferment loan:	2,219,176
Deferred revenue grant - Sales tax deferment - amortisation for the year 2021-22	3,875,416
Current maturity value during the year 2021-22 (Payable)	2,719,070
Total	8,813,662

Phyto Chem - Annual Report - 2020-21

Notes to financial statements for the year ended 31st March 2021

(All amounts in Lakhs, except otherwise stated)

Note 41:

Confirmation of balances of certain parties for amounts due to them / due from them as per the accounts of the Company have not been received due to Covid Pandemic environment and complete lockdown in our country. However the values in the book of accounts are final as they have not furnished the confirmation of balance certificate before the due date prescribed by the Company.

Note 42:

In the opinion of Board of Directors of the Company, current assets, loans and advances and deposits are approximately of the value stated in the accounts, if realized in ordinary course of business, unless otherwise stated. The provisions for all known liabilities are adequate and not in excess of the amounts reasonably necessary.

Note 43:

The Company is required to furnish details under section 22(1) to 22(5) of The Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act) read with Para FV of General Instructions for Balance sheet in Division II of Schedule III of the Companies Act, 2013. As per the said Regulations the Company seeks information from the suppliers about Registration particulars from them for furnishing the information.

Disclosure in respect of principal and interest pertaining to the Micro, Small and Medium Enterprises Dev. Act, 2006 based on available details is as under

Particulars	As at 31 st March 2021	As at 31 st March 2020
a. Principal amount due to suppliers registered under the MSMED Act and remaining unpaid as at year end. (all dues were paid before year end).	-	-
b. Interest due to suppliers registered under the MSMED Act and remaining unpaid as at year end;	Nil	Nil
c. Interest paid, under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year.	Nil	Nil
d. Principal payment made to suppliers registered under the MSMED Act, beyond the appointed day during the year.	Nil	Nil
e. Interest paid, other than under section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year.	Nil	Nil
f. Interest due and payable for the year amount of interest accrued and remaining unpaid at the end of each year towards suppliers registered under MSMED Act, for payments already made; and	Nil	Nil
g. Further interest remaining due and payable for even in succeeding years.	Nil	Nil

Note: There are no outstanding amounts to Micro, Small and Medium Enterprises as on 31-03-2021.

Note 44:

The Company has loss of Rs.26,60,159 (net) due to fluctuations in foreign exchange rate and the same is debited to P&L A/c.



Phyto Chem (India) Limited

Notes to financial statements for the year ended 31st March 2021

(All amounts in Lakhs, except otherwise stated)

Note 45:

a. Value of Imports calculated on CIF basis by the Company:

Particulars	Year ended 31 st March 2021 (Rs.)	Year ended 31 st March 2020 (Rs.)
i. Raw materials:	56,121,300	44,200,000
ii. Components and spare parts:	Nil	Nil
iii. Capital Goods:	Nil	Nil
b. Expenditure in foreign currency during the Financial year on account of royalties, know how, professional, consultation and other matters: Nil		
c. Total value of imported raw material consumed during the Financial year and the total value of indigenous raw materials and the percentage of each to the total consumption:		

I. Raw material consumption (Product wise):

Particulars	Year ended 31 st March 2021 (Rs.)	Year ended 31 st March 2020 (Rs.)
a. Technicals	321,577,167	305,970,686
b. Solvents, emulsifiers & others	9,871,106	13,143,133
Total	331,448,273	319,113,819

II. Raw Material consumption (Percentage)

	Year ended 31 st March 2021			Year ended 31 st March 2020		
	Qty (Kgs.)	Rs.	Percentage of Consumption	Qty (Kgs.)	Rs.	Percentage of Consumption
a. Imported	72,799	85,164,409	8.22	22,496	17,380,720	2.40
b. Indegeneous	812,424	246,283,864	91.78	915,698	291,889,325	97.60
Total	885,223	331,448,273	100.00	938,194	309,270,045	100.00

Note 46: Income and expenditure in foreign currency and foreign currency exposures:

a. Earnings in foreign currency:

Particulars	As at 31 st March 2021	As at 31 st March 2020
FOB value of exports	-	-

b. Expenditure in foreign currency:

Particulars	As at 31 st March 2021	As at 31 st March 2020
i. Commission paid	-	-
ii. Freight and CFS	2,734,471	1,154,264
iii. Machinery and spares	-	-
iv. Printing and stationery	-	-
v. Subscriptions & others	-	-

c. Earnings in foreign exchange : Nil

Phyto Chem - Annual Report - 2020-21

Notes to financial statements for the year ended 31st March 2021

(All amounts in Lakhs, except otherwise stated)

Note 47:

Particulars	Qty (Lts/Kgs/Sft.)	Year ended 31 st March 2021 (Rs.)	Qty (Lts/Kgs/Sft.)	Year ended 31 st March 2020 (Rs.)
a. Particulars of capacity, Production and sales				
i. Installed Capacity (Lts)	9,000,000		9,000,000	
ii. Production (Lts)				
Pesticides Formulations	768,029		876,831	
iii. Sales				
1. Pesticides Formulations (Lts)	631,493	452,927,164	956,869	456,053,558
2. Real Estate (Sft.)	-	-	-	-
		<u>452,927,164</u>		<u>456,053,558</u>
b. Details of Opening and Closing Stock:				
Finished Goods				
i. Pesticides Formulations				
Opening Stock (Lts)	224,500	76,834,273	304,538	83,518,706
Closing Stock (Lts)	361,036	92,174,009	224,500	76,834,273
ii. Land - Real Estate				
Opening Stock (Sft.)	48,395	9,679,000	48,395	9,679,000
Closing Stock (Sft.)	48,395	9,679,000	48,395	9,679,000

Note 48:

Previous year figures have been regrouped / rearranged wherever necessary to make them comparable.

Note 49:

Figures shown in the Financial Statements have been rounded off to the nearest Rupee.

Note 50:

Estimation uncertainty relating to the global health pandemic on COVID-19:

The Covid-19 continues to spread across the globe and India, which has contributed to a significant decline and volatility in global and Indian Financial Markets and a decrease in the economic activities given the virulent nature of the pandemic situation, the carrying value of the Company's receivables as at 31st March 2021 have not been affected by the severity and duration of the outbreak. However the Company believes that it has taken into account all the possible impact of known events arising out of Covid-19 pandemic in the preparation of financial results resulting out of fair valuation of these receivables. However, the impact assessment of Covid-19 is a continuing process given its nature and duration. The Company will continue to monitor for any material changes in this regard.

As per our Report of even date attached

For and on behalf of the Board of Directors

For M/s S.T. Mohite & Co.,
Chartered Accountants
Firm Regn. No. 011410S

Y.Nayudamma
Managing Director
DIN : 00377721

G.S.R.Anjaneyulu
Director
DIN : 01874325

Sreenivasa Rao. T. Mohite
Partner, M.No.015635
UDIN: 21015635AAAADH6685

Pavansingh Thakur
Company Secretary
M.No: 56920

B. Sambasiva Rao
Chief Financial Officer

Place : Hyderabad
Date : 30th June 2021

Place : Hyderabad
Date : 30th June 2021



Phyto Chem (India) Limited



Phyto Chem (India) Limited

(CIN: L24110TG1989PLC009500)

Survey No.628, Temple Street, Bonthapally - 502 313,
Gummadidala Mandal, Sangareddy District, Telangana State.

Attendance Slip

**The Company does not have the practice of providing gifts to
Members at the Annual General Meeting**

32nd Annual General Meeting on 27th September 2021

1. Name & Registered Address of the
Sole / first named Shareholder :
2. Name(s) of the Joint Shareholder(s) (if any) :
3. Registered Folio No./ DP ID / Client ID No. :
4. Number of Shares held :

I certify that I am a member / Proxy for the member of the Company. I hereby record my presence at the 32nd Annual General Meeting of the Company at Registered Office of the Company at Survey No.628, Temple Street, Bonthapally-502 313, Gummadidala Mandal, Sangareddy District, Telangana State on Monday, 27th September 2021 at 11:45 A.M.

Member's / Proxy's Name in Block Letters

Member's / Proxy's Signature

SUBJECT : E-VOTING

In terms of the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (hereinafter called "the Rules") and Regulation 44 of the SEBI (LODR) Regulations, 2015, the Company is providing facility to exercise votes on the items of business given in the Notice through electronic voting system, to members holding shares as on 20th September 2021 (End of Day) being the cut-off date (i.e. record date for the purpose of Rule 20(3)(vii) of the Rules) fixed for determining voting rights of members, entitled to participate in the e-voting process, through the e-voting platform provided by Central Depository Services Limited (CDSL).

The e-voting particulars are set out below:

EVSN (E-Voting Sequence Number)	USER ID	PASSWORD
210825010	Please refer Notes No.8 d & 8 e of e-voting instructions in the Notice.	

The e-voting period commences from 9:00 a.m. on 24th September 2021 and ends on 26th September 2021 by 5:00 p.m. The members of the Company, holding shares either in physical or demat form, as on the cut-off date of 20th September 2021, may cast their vote electronically.

For instructions on e-voting, please read the attached Notice of the Annual General Meeting. This communication forms an integral part of the Notice for convening the Annual General Meeting of the Company to be held on 27th September 2021.

Phyto Chem - Annual Report - 2020-21



Phyto Chem (India) Limited

(CIN: L24110TG1989PLC009500)

Survey No.628, Temple Street, Bonthapally - 502 313,
Gummadidala Mandal, Sangareddy District, Telangana State.

Proxy Form

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rule, 2014.

CIN	L24110TG1989PLC009500
Name of the Company	Phyto Chem (India) Limited
Corporate office	No.8-3-229/23, First Floor, Thaherville, Yousufguda Checkpost, Hyderabad - 500 045, Telangana State.
Registered office	Survey No.628, Temple Street, Bonthapally-502 313, Gummadidala Mandal, Sangareddy District, Telangana State.
Name of the Member(s)	
Registered Address	
Email Id	
Folio No / Client ID	DP ID:

I/ We, being the member(s) of _____ shares of the above named Company, hereby appoint

1	Name		
	Address	Signature	
	E- Mail ID		
	or failing him		
2	Name		
	Address	Signature	
	E- Mail ID		
	or failing him		
3	Name		
	Address	Signature	
	E- Mail ID		
	or failing him		

As my / our proxy to attend and vote (on a poll) for me / us and on my / our behalf at the 32nd Annual General meeting of the Company, to be held on Monday the 27th day of September 2021 at 11:45 A.M. at the Registered Office of the Company at Survey No.628, Temple Street, Bonthapally 502 313, Gummadidala Mandal, Sangareddy District, Telangana State and at any adjournment thereof in respect of such resolutions as are indicated below:



Phyto Chem (India) Limited

Item No.	Resolutions	For	Against
1.	Adoption of the Audited Financial Statements, Reports of the Board of Directors and Auditors for the year ended 31 st March 2021.		
2.	Re-appointment of Dr. Sreemannarayana Prathipati (DIN: 00377472) as Director who retires by rotation		
3.	Continuation of Directorship of Dr. Sreemannarayana Prathipati (DIN: 00377472) as a Non-Executive Non-Independent Director in terms of Regulation 17(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.		


Affix Revenue Stamp

Signed thisday of2021

Signature of Shareholder.....

Signature of Proxy holder(s).....

Route Map to Registered Office - AGM on 27-09-2021



Phyto Chem - Annual Report - 2020-21



Our Company Products



Printed Matter

If undelivered, Please return to :



Phyto Chem (India) Limited

CIN : L24110TG1989PLC009500

Survey No. 628, Temple Street, Bonthapally - 502 313,
Gummadidala Mandal, Sangareddy District, Telangana State.

Leo Printers @ 9866353646